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Trends in the Timeliness of HIV Diagnosis and Antiretroviral Treatment (ART) Initiation before, during 
and after the “Treat All” Recommendation – New York City, 2006-2015: A Case Study 
by 
McKaylee M. Robertson 
 
Advisor: Denis Nash, MPH PhD 
BACKGROUND: Voluntary HIV testing followed by immediate antiretroviral treatment (ART) initiation 
(universal testing and treatment) has become an integral part of strategies to eliminate HIV and control 
the HIV/AIDS epidemic. Minimizing the time from HIV infection to ART initiation is essential for universal 
test and treatment to be optimally effective. In New York City, an epicenter of the HIV epidemic, the 
‘treat all’ recommendation, immediate treatment for all people diagnosed with HIV, was made in late 
2011, and efforts to ‘treat all’ were contemporaneous with large scale HIV testing initiatives in NYC. The 
overarching goal of this dissertation was to examine trends in the timeliness of diagnosis and ART 
initiation using data from the population-based New York City HIV surveillance registry before, during 
and after the “treat all” recommendation. 
METHODS:  I utilized data from the New York City population-based HIV surveillance registry to assess 
the timing of diagnosis and ART initiation in New York City. For aim 1, to describe and quantify trends in 
early diagnosis (e.g., examine median CD4 count at diagnosis and proportion of acute HIV cases among 
all new diagnoses) and early ART initiation (e.g., proportion with CD4 count >500 at ART initiation), I 
used data on NYC residents diagnosed from 2012-2015. For aim 2, to estimate the time from 
seroconversion to diagnosis, we applied published estimates of CD4 decline after infection from 
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seroconverter cohorts to our population, NYC residents newly diagnosed with HIV. To verify the 
assumption that the square root of the CD4 cell count decreases linearly over time prior to antiretroviral 
treatment (ART) initiation, we compared estimates of diagnosis delay  based on first versus second pre-
ART CD4 counts, using data on NYC residents diagnosed from 2006-2015 (sub-aim 2a). Finally, using 
methods developed in Aim 2, we estimated the time from HIV seroconversion to diagnosis and to ART 
initiation among NYC residents diagnosed from 2006-2015 for aim 3. 
RESULTS: In the first aim, I examined the timeliness of diagnosis and treatment initiation in the universal 
test and treatment era. Among 9987 NYC residents with HIV diagnosed from 2012 to 2015, diagnosis 
was early (a CD4 cell count ≥500/μL or diagnosed with acute HIV infection) in 35%, and 87% started ART 
by June 2017. The annual proportion of persons with early diagnosis did not increase appreciably (35% 
in 2012 vs 37% in 2015; P = .08, Cochran-Armitage test for trend). Overall, 69% of persons had started 
ART at 6 months after diagnosis. The time from diagnosis to ART initiation decreased from year to year. 
Within 6 months of diagnosis, 62%, 67%, 72% and 77% of persons with HIV diagnosed in 2012, 2013, 
2014, or 2015, respectively, had started ART, with median (interquartile range) times to ART initiation of 
3.34 (1.34–12.75), 2.62 (1.28–10.13), 2.16 (1.15–7.11), and 2.03 (1.11–5.61) months, respectively. 
In the second aim, I adapted a CD4 decline model to estimate diagnosis delay (time from 
seroconversions to diagnosis). Among 12,849 NYC residents who were diagnosed with HIV from 2006 to 
2015 with at least 2 pre-ART CD4 count measurements around time of diagnosis, the average diagnosis 
delays based on the first or second pre-ART CD4 count were similar (4.93 years (95% Confidence 
intervals (CI):4.84-5.03) and 4.85 years (95% CI:4.76-4.95), respectively, p-value=0.09, Wilcoxon signed-
rank).  
In the third aim, I used methods developed in Aim 2 to estimate the timing of seroconversion and 
estimated the timeliness of diagnosis and treatment initiation. Among 28,162 people diagnosed with 
HIV during 2006-2015, 89% initiated ART by June 2017. The median CD4 count at diagnosis increased 
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from 326 (Interquartile range (IQR):132-504) to 390 (IQR:216-571) cells/µL from 2006-2015. The average 
time from estimated seroconversion to ART initiation decreased by 33% from 8.0 years (95% confidence 
interval [CI]:7.8-8.2) in 2006 to 5.4 years (95%CI: 5.1-5.6) in 2015. Contributing to the reduction in time 
to ART initiation, the average time from estimated seroconversion to diagnosis decreased by 22%, from 
6.5 years (95% CI:6.3-6.7) to 5.1 years (95% CI:4.9-5.4) from 2006-2015, and the average time from 
diagnosis to ART initiation reduced by 87%, from 1.5 years (95% CI:1.4-1.5) to 0.2 years (95% CI:0.2-0.3) 
from 2006-2015. 
DISCUSSION: The time to ART initiation was reduced in tandem with expanded HIV testing and 
treatment efforts in New York City. We found considerable progress in rapid ART initiation: a) the 
proportion of persons initiating ART within 6 months of diagnosis increased from 2012 to 2015, b) the 
time from seroconversion to ART initiation decreased by 33% over a 10 year period, and c) the time 
from diagnosis to ART initiation decreased by 87%, and is now on average very short. Despite these 
improvements, disparities persist in the ART initiation delay so efforts should focus on subgroups for 
whom progress still needs to be made. Finally, substantive efforts are needed to reduce delays in 
diagnosis (i.e., the time from seroconversion to diagnosis). Targeted HIV testing strategies are needed to 
more rapidly identify people with undiagnosed HIV soon after HIV seroconversion in order to achieve 
further reductions in HIV incidence and mortality in key subgroups who continue to be negatively 
impacted by the HIV epidemic.    
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CHAPTER 1. INTRODUCTION 
INTRODUCTION  
The Joint United Nations Programme on HIV/AIDS (UNAIDS) plan to control the global HIV/AIDS 
epidemic emphasizes the need to focus the public health response locally, on the cities and communities 
most affected by HIV.1 New York State is an epicenter of the epidemic, and in 2015, the state had the 
second highest number of people living with HIV infection (N=139,900; 95% Confidence intervals: 
133,900-146,000) and the fourth highest number of new infections (N=3,400, 95% CI: 2,800-4,000) in 
the United States.2 Similar to many jurisdictions around the world, New York State is embarking on an 
effort to control the HIV/AIDS epidemic via reducing the annual estimated number of new HIV infections 
and achieving the first ever decrease in HIV prevalence in the state.3 To control the epidemic in New 
York and elsewhere, we must minimize the infectious period (i.e., the time a person is not on treatment) 
and ultimately help people living with HIV achieve sustained viral suppression, thereby decreasing HIV-
related morbidity and mortality and preventing onward spread of HIV.3-6  
The achievement of timely viral suppression requires prompt testing and diagnosis following HIV 
seroconversion—typically an unobservable event—and timely initiation of antiretroviral treatment 
(ART). Timely diagnosis is necessary, as persons unaware of their HIV infection accounted for 15% of all 
persons living with HIV-infection in 2015 and approximately 40% of ongoing transmissions in the United 
States.7,8 Generally, the timeliness of diagnosis and ART initiation is assessed by examining the 
distribution of CD4 count at diagnosis and ART initiation, respectively, or with static measures (e.g., the 
proportion of people who initiate ART). In New York City (NYC), increases in CD4 counts at diagnosis and 
ART initiation suggest a trend toward earlier diagnosis and treatment initiation.9 Yet, in 2015 more than 
one in six (17%) NYC residents newly diagnosed with HIV were diagnosed late (i.e., an AIDS diagnosis 
within 31 days of HIV diagnosis), and one-quarter of NYC residents who were diagnosed with HIV in 
2015 had not initiated ART as of 6 months post-diagnosis.10,11  At the national level, CD4 information is 
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rarely disseminated, beyond tracking immunologically defined AIDS (CD4 <200 cells/μL), and data on the 
timeliness of ART prescriptions is not published due to small sample sizes of systematically collected ART 
information on newly diagnosed people.2,12 Thus, a gap exists between guidelines, which recommend 
ART initiation at diagnosis for all people living with HIV (PLWH), and the reality of when people start 
treatment. And a gap exists in metrics for monitoring the care continuum, as they do not provide any 
information on the amount of time that passes between infection and diagnosis and ART initiation.13,14  
In 2016, the US Centers for Disease Control and Prevention developed a new statistical method, 
referred to as the “CD4 depletion model”, to generate national estimates of HIV incidence, and this 
technique could be adapted to estimate the time from seroconversion to diagnosis and to ART 
initiation.15 Adapting such a model to local data is critical to understanding local epidemics and shaping 
local program implementation and policy designed to minimize the time elapsed since seroconversion.  
OVERVIEW OF THE DISSERTATION, AIMS AND HYPOTHESES 
Using data from the population-based NYC HIV surveillance registry, we propose to conduct a 
longitudinal assessment of trends in HIV diagnosis and ART initiation and to quantify the amount of time 
that elapses from seroconversion to ART initiation.  
Aim 1:  Among NYC residents diagnosed with HIV from 2012-2015 (N=9,987) describe and quantify 
trends in early diagnosis (e.g., median CD4 count at diagnosis or proportion of acute HIV cases 
among all new diagnoses) and early estimated ART initiation (e.g., proportion with CD4 count 
>500 at ART initiation) for the city overall and by demographics (e.g., by gender and 
race/ethnicity)  
H1: Compared to 2012, more people in 2015 are being diagnosed early and initiating ART early  
H2: Whites and men who have sex with men will have earlier diagnosis and ART initiation 
Aim 2:  Adapt a CD4 decline model to estimate the timing of HIV seroconversion among those with 
newly diagnosed HIV in NYC   
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Sub-aim 2a: Assess the linear decline assumption using the second CD4 reported to the registry 
Sub-aim 2b: Validate the adapted model using data from the Case-Surveillance-Based Sampling 
Project 2012-2014 (N=134) by comparing the mean distribution of estimated seroconversion 
dates with information on last negative and first positive HIV test dates  
Aim 3:  Among NYC residents diagnosed with HIV from 2006-2015 (N=28,150), estimate the time from 
HIV seroconversion to diagnosis, and the time from HIV seroconversion to ART initiation, changes in the 
metrics over-time and changes among populations of interest  
 H3: The time from seroconversion to ART initiation will decrease from 2006-2015  
 H4: Women, blacks, Latinos/Hispanics and people with a history of injection drug use will have 
longer delays  
GAPS IN THE LITERATURE 
Overview. The infectious period starts at HIV-seroconversion and ends when HIV viral load is 
suppressed following treatment initiation.5 A critical barrier to understanding the average period of 
infectiousness is that seroconversion is often an unobservable event. This dissertation seeks to address 
that barrier via the development and assessment of a local measure of seroconversion based on the first 
pre-treatment CD4 count reported to the surveillance registry after HIV diagnosis.  
The development of a valid method to estimate the timing of seroconversion would allow for more 
complete characterization of local HIV epidemics. Researchers and implementers generally do not know 
the amount of time that passes from HIV-seroconversion to diagnosis and to treatment initiation (i.e., 
the HIV-infectiousness period; aim 3) at the population level in their local epidemics.13,16 Estimating the 
timing of seroconversion will allow for identification of groups for public health intervention (e.g., 
people with a long HIV-infectiousness period) and evaluating the implementation and uptake of 




The timing of seroconversion is almost never known. And inferring a date of HIV-infection is difficult 
because people are rarely diagnosed during primary or acute HIV infection (AHI), the first stage of HIV-
infection.20 Rather, most people are diagnosed in the later stages of HIV infection when the duration of 
the infection is much less certain.  
Assuming no treatment has been received, the CD4 cell count at diagnosis has been proposed to 
estimate the time since infection at the date of first CD4 test. In seroconverter cohort studies, the 
trajectory of CD4 decline, on a square root scale, has typically been modeled as a linear function of the 
time since infection.21-23 Using model parameters (i.e., the slope and intercept estimates of CD4 decline) 
from the CASCADE seroconverter cohort study for subgroups of interest in the US (e.g., CD4 at 
seroconversion and annual decline estimates for men aged 25-29) and linear extrapolation, researchers 
have estimated the distribution of delay from seroconversion to diagnosis in the United States.15,16 
Recently (March 2019), the Centers for Disease Control and Prevention (CDC) presented national 
estimates of the time from seroconversion to viral suppression as part of a conference presentation.24 
To the best of our knowledge, the CD4 decline approach has not been validated or applied at the local 
level.15,16  
The linear decline assumption of the CD4 decline approach needs to be verified. Estimated delays in 
diagnosis rely on the accuracy of the initial CD4 depletion model, which assumes the mean square root 
of CD4 count is linearly related to the time since seroconversion. Some evidence suggests the rate of—
square root transformed—CD4 decline over time is nonlinear.25 
Characterizing the statistical uncertainty around estimates of the time since seroconversion is 
critical for epidemiologists and implementers. The CD4 decline approach developed by the CDC 
represents a method for local HIV surveillance jurisdictions to generate estimates of diagnosis delay. 
However, the CDC authors have not developed an approach for incorporating variance around their 
national estimates of the infectious period.15 
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The HIV infectiousness period is rarely quantified. Randomized controlled trials have established 
that early effective combination ART improves the prognosis of HIV-infected people and reduces HIV 
morbidity and mortality, as well as reduces HIV-transmission.5,6,26,27 As a result of this and earlier 
observational study evidence, many local, national and global regulatory and programmatic bodies, 
including New York State, recommend all people diagnosed with HIV initiate treatment, regardless of 
CD4 count and recommend using Voluntary HIV testing followed by immediate ART initiation (universal 
testing and treatment) as one part of a combination of approaches to eliminate HIV and to help control 
the AIDS epidemic.3,28,29 
One aim of UTT is to minimize the time from HIV infection to ART initiation, and ultimately help 
people living with HIV achieve sustained or durable viral suppression in order to prevent onward HIV 
transmission and reduce morbidity and mortality.30,31 Minimizing this window requires that people are 
diagnosed and linked to care early in the course of HIV infection. Due to the inherent difficulty of 
creating a population-representative incident cohort (i.e., a cohort where HIV-seroconversion is 
observed) and an absence of methods for estimating seroconversion in population-representative 
seroprevalent cohorts, very few studies have developed population-based estimates of the time 
between seroconversion and diagnosis and all published estimates are for the country/national 
level.13,15,16,32 According to a CDC conference presentation, in the United States, people diagnosed with 
HIV in 2016 had been infected an estimated 39 months before diagnosis compared with an estimated 43 
months among people diagnosed in 2012.24   
An HIV-infected individual’s CD4 cell count is a marker of time since infection: the lower the count, 
the longer (on average) the individual has been infected. In NYC, from 2006 to 2012, the median CD4 
count at diagnosis increased from 325 cells/µl to 379 cells/µl.33 This data suggests that people are being 
diagnosed earlier in the course of infection. However, the elapsed time from seroconversion to 
diagnosis is unknown, making it difficult for jurisdictions to target resources accordingly to improve this 
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outcome. Moreover, if CD4 decline varies among population (e.g., by transmission risk group), then the 
average CD4 at diagnosis is not fully informative about the timeliness of diagnosis for subgroups, and  
estimates of time since seroconversion at the subgroup level could help suggest new or enhanced 
interventions to reduce diagnosis delay.  
Furthermore, population-level data on how much time passes from HIV seroconversion to treatment 
initiation in the United States do not exist. Arguably, the primary reason these data do not exist is 
because the timing of seroconversion is almost never known and because population-based data on the 
timing of ART initiation is not collected in routine surveillance. Consequently, data on ART initiation is 
limited to clinical cohorts or to small numbers of newly diagnosed persons.34,35 Evidence suggests, 
however, that the time from seroconversion to ART initiation has decreased among certain populations. 
Among a cohort of injection drug users in Baltimore, no significant trend toward improvement in the 
CD4 count at treatment initiation was observed.36 In San Francisco from 2007-2011 and in NYC from 
2006-2013, surveillance data indicated a trend toward earlier ART initiation, as demonstrated by 
increases in CD4 cell count at ART initiation9,37 Thus, in some populations the time from seroconversion 
to ART initiation is decreasing but the exact duration of time that passes (e.g., two versus three years) 
from seroconversion to treatment initiation is unknown. To further support TasP efforts, estimates of 
the time from seroconversion to ART initiation could be a priority indicator to identify gaps in time and 
monitor whether HIV prevention initiatives are closing such gaps. 
PUBLIC HEALTH IMPLICATIONS 
The dissertation addresses four knowledge gaps in the literature around quantifying the infectious 
period for HIV and the related treatment delay. First, the timing of HIV seroconversion has not been 
estimated or validated at the local population level (Aim 2). Second, the length of the HIV-infectiousness 
period has not been quantified (Aim 3). Third, for the CD4 decline approach developed by CDC, a 
method to characterize the uncertainty around estimates of diagnosis delay does not exist (Aim 2). 
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Fourth, the linear decline assumption of the CD4 decline approach needs to be verified (Aim 2a). If the 
aims of the project are achieved, this dissertation will improve understanding of the NYC HIV epidemic 
and will provide researchers with a novel approach for estimating seroconversion and monitoring and 
evaluating efforts to control the HIV epidemic. Given that all states, the District of Columbia and U.S. 
territories have mandatory reporting of all diagnosed cases of HIV infection,15 and most have 
comprehensive reporting of HIV-related laboratory tests, the development of such a method will have 
broad implications and utility in terms of monitoring the epidemic and progress toward controlling the 
epidemic.  
OVERVIEW OF METHODOLOGICAL APPROACHES 
I utilized data from the New York City population-based HIV surveillance registry to assess the timing 
of diagnosis and ART initiation in New York City. For aim 1, to describe and quantify trends in early 
diagnosis (e.g., examine median CD4 count at diagnosis and proportion of acute HIV cases among all 
new diagnoses) and early ART initiation (e.g., proportion with CD4 count >500 at ART initiation), I used 
data on NYC residents diagnosed from 2012-2015. For aim 2, to adapt a CD4 decline model to estimate 
the timing of HIV seroconversion among those with newly diagnosed HIV, we used data on NYC 
residents diagnosed from 2006-2015 and the first pre-treatment CD4 count. We applied published 
estimates of CD4 decline after infection from seroconverter cohorts to our population to infer timing of 
seroconversion.15,16 We assessed the linear decline assumption using data on NYC residents diagnosed 
from 2006-2015 with at least 2 CD4 counts reported before ART initiation (i.e., to examine differences in 
time from seroconversion to diagnosis based on first versus second CD4 count) (sub-aim 2a). Using data 
on NYC residents who completed an interview for the Case-Surveillance-Based Sampling Project from 
2012-2014, we compared estimated diagnosis delays with self-reported diagnosis delays (sub-aim 
2b).For aim 3, to estimate the time from HIV seroconversion to diagnosis and to ART initiation, we used 
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data on NYC residents diagnosed from 2006-2015. A detailed description of the methods is found in 
subsequent chapters (for aim 1 see chapter 2, aim 2 see chapter 3, and aim 3 see chapter 4).  
CONCLUSIONS 
Minimizing the time from HIV infection to ART initiation is essential for universal test and treat to be 
optimally effective.31 However, researchers have not typically focused on quantifying the HIV-
infectiousness period, partially due to the absence of data on the timing of seroconversion. In the 
universal test and treat era, an estimate of the infectious period from HIV seroconversion to ART 
initiation could become a priority indicator to identify gaps in time and monitor whether HIV prevention 
initiatives are closing such gaps. This dissertation has laid the groundwork for a new metric for 
monitoring treatment initiation and has advanced our understanding of the timeliness of diagnosis and 
ART initiation. This novel method can be adopted by other researchers and surveillance jurisdictions to 
monitor HIV epidemics and the impact of universal test and treat policies and programs on the HIV 
epidemic. 
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CHAPTER 2: TIMELINESS OF HIV DIAGNOSIS AND ANTIRETROVIRAL 
TREATMENT INITIATION IN THE ERA OF UNIVERSAL TEST AND TREAT 
(AIM 1)  
ABSTRACT  
Background: We describe the timing of HIV diagnosis and antiretroviral treatment (ART) initiation 
following implementation of universal test and treatment policies in New York City (NYC).   
Methods: Using NYC population-based HIV Registry data for persons diagnosed from 2012 through 2015 
and followed  through June 2017, we examined trends in the proportion diagnosed early following HIV 
infection (i.e., with CD4 count ≥500 cells/mm or with acute HIV infection) and used Kaplan-Meier plots 
and proportional hazards regression to examine the timing of ART initiation following diagnosis.  
Results: Among 9,987 NYC residents diagnosed with HIV from 2012-2015, 35% were diagnosed early and 
87% initiated ART by June 2017. The annual proportion of persons diagnosed early did not increase 
appreciably (35% in 2012 versus 37% in 2015, p=0.08). By 6 months following diagnosis, 62%, 67%, 72% 
and 77% of persons diagnosed in 2012, 2013, 2014 or 2015, respectively, had initiated ART, with 
respective median time (months) to ART initiation of 3.34 (Interquartile range: 1.34-12.75), 2.62(1.28-
10.13), 2.16(1.15-7.11), 2.03(1.11-5.61).  
Conclusions: While recommendations for ART initiation upon diagnosis are increasingly being 
implemented, these finding suggest immediate treatment initiation is not universal. Continued efforts 





People with HIV (PWH) have a lower risk of developing acquired immunodeficiency syndrome 
(AIDS), serious illnesses, and death if they start taking antiretroviral treatment (ART) when the CD4-
lymphyocyte (CD4) count is above 500 cells/mm3.1,2 Furthermore, early initiation of ART decreases risk 
of HIV transmission.3 Because of this and other evidence in favor of early ART for PWH, by 2012 the 
United States Department of Health and Human Services expanded HIV treatment guidelines from the 
recommendation that PWH with a CD4 count <500 cells/mm start treatment to the recommendation of 
ART initiation after diagnosis for all persons with HIV, regardless of CD4 count.4,5  
Voluntary HIV testing followed by immediate ART initiation (universal testing and treatment) has 
become an integral part of strategies to eliminate HIV and control the HIV/AIDS epidemic.4-11 Efforts 
aimed at ending the epidemic rely on a) high population-level ART coverage and b) early ART initiation 
to achieve the full potential impact of universal testing and treatment, for individual health outcomes 
for PWH and for HIV incidence reduction.1,2,6,11,12  
To attain the goals of universal test and treat and end the HIV epidemic, we must monitor the 
timeliness of diagnosis and ART initiation at the population-level. Yet, population-based data on ART 
initiation are generally not available because ART initiation and prescription are typically measured 
indirectly by public health departments (e.g., with viral suppression as a proxy) or with data from non-
population-based sources (e.g., clinical cohorts).13-16 Data from the Medical Monitoring Project can be 
used to examine population-based trends in ART initiation nationally, but local data are limited.17 
Moreover, as the HIV care cascade has become the predominant visual representation of the HIV 
epidemic, much of the focus has been on the proportion diagnosed and receiving ART rather than the 
elapsed time from infection to diagnosis and to ART initiation.18  
The aim of this analysis was to understand a) the timeliness of HIV diagnosis and ART initiation 
relative to infection by examining trends in CD4 counts, and b) the time from diagnosis to ART initiation 
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and predictors of ART initiation in the era of universal testing and treatment  using population-based 
New York City (NYC) HIV surveillance data.  
METHODS 
Data source and population 
The Department of Health and Mental Hygiene has conducted population-based, name-based AIDS 
surveillance since 1981 and HIV surveillance 2000.19 Electronic reporting of all HIV-related laboratory 
tests, including positive diagnostic tests, viral load (VL), CD4 and viral nucleotide sequences, has been 
mandatory under NYS law since 2005. Validation work  has shown that over 85% of CD4 cell counts and 
VL tests reported to surveillance were associated with primary (versus urgent/emergency) care, making 
CD4 and VL laboratory reports in the surveillance system reasonable indicators of receipt of HIV medical 
care in NYC. 20 21-23 Demographic and HIV transmission risk information is obtained via review of medical 
charts of persons newly diagnosed with HIV. Vital status is routinely updated through matches with 
death records.  
This analysis included NYC residents diagnosed with HIV from 2012 to 2015 and aged >13 years at 
HIV diagnosis and their laboratory information reported through June 30, 2017. We excluded persons 
who did not have at least one VL or CD4 reported to the Registry within 18 months of diagnosis, as these 
persons were most likely not receiving medical care in NYC and would not have laboratory data reported 
to the Registry.  
This study was approved by the institutional review boards at The City University Of New York and 
the New York City Department of Health and Mental Hygiene. For these secondary analyses of de-





The CD4 count at diagnosis was defined as the first CD4 count within 6 months of the HIV diagnosis 
date. The CD4 count at diagnosis was categorized as CD4≥500 cells/mm3, CD4<500 cells/mm3, or CD4 
not reported within 6 months of diagnosis. Persons were considered to have an early diagnosis if the 
CD4 count was ≥500 cells/mm3 or if they had acute HIV infection (AHI) at diagnosis.23 AHI was based on 
clinical laboratory results per the Centers for Disease Control and Prevention surveillance case 
definition,23 for example, a negative or indeterminate Western Blot and a detectable VL.24 
Antiretroviral Initiation 
 ART initiation was defined based on the earlier occurrence of either: a ≥1-log drop in detectable VL 
(defined as ≥200 copies/mL) over a 3-month period or a detectable VL followed by an undetectable VL 
(defined as <200 copies/mL).25,26 The date of probable ART initiation was defined as the mid-point 
between the two VLs which indicated ART initiation. We also considered ART initiation to have occurred 
if the first VL reported to the Registry was undetectable. In this case the estimated date of ART initiation 
was the mid-point between diagnosis and the undetectable VL.  
The CD4 count at ART initiation was the CD4 count closest to and within the 3 months before the 
estimated date of ART initiation. For persons not known to have AHI at diagnosis, early ART initiation 
was defined as a CD4 count >500 cells/mm at ART initiation. If the CD4 count was not available at ART 
initiation, the timing of ART initiation was considered to be ‘unknown’. As persons diagnosed with AHI 
could be misclassified as having lower CD4 counts at ART initiation, we used the timing of ART initiation 
after diagnosis to define early ART initiation. For persons diagnosed with AHI, early ART was defined as 
ART initiation within 6 months after diagnosis.  
Covariates  
We examined the following covariates as predictors of ART initiation: sex, age at HIV diagnosis, 
race/ethnicity, HIV transmission risk group, year of diagnosis, CD4 count at diagnosis, linked to HIV 




We performed descriptive analysis of demographic characteristics stratified by early diagnosis, CD4 
<500 units at diagnosis and unknown timing of diagnosis relative to infection (i.e., AHI or CD4 ≥500 
cells/mm at diagnosis versus CD4 <500 cells/mm at diagnosis versus unknown CD4 at diagnosis, 
respectively). To examine the timeliness of diagnoses relative to infection, we examined the annual 
proportion of persons diagnosed early (i.e., CD4≥500 cells/mm or with AHI at diagnosis) using the 
Cochran-Armitage test for trend.  
To examine the timeliness of ART initiation, we created Kaplan Meier plots and stratified by year of 
diagnosis overall and for all covariates. The log-rank test was used to examine the statistical significance 
of annual improvements in time to ART initiation for all covariates. To examine characteristics of 
persons who initiated ART, we used proportional hazards regression. The median time to ART initiation 
and the proportion who initiated ART at 6 months were generated using Kaplan-Meier product-limit 
estimates. For Kaplan-Meier plots and proportional hazards regression, persons contributed time in 
months from diagnosis to the estimated date of ART initiation, or they were censored at the earlier of 
death or June 30, 2017.  
We also examined temporal trends in median CD4 counts at diagnosis and at ART initiation using 
quantile regression as an indicator for the timeliness of diagnosis and ART initiation, respectively; we 
modelled the median CD4 count at diagnosis and at ART initiation as a linear function of the calendar 
year of diagnosis.28 For the quantile regression we assume that lower CD4 counts indicate a longer time 
since HIV infection. Therefore, we ran these models with and without AHI cases, as at the time of AHI 
there is sometimes high viral replication which results in a drop in CD4 count.29 




The analysis included 9,987 NYC residents who were diagnosed with HIV from 2012-2015 (median 
CD4 at diagnosis 382; interquartile range (IQR) 208-564) (Table 1). Of these, more than one-third (35%, 
N = 3,511) were diagnosed early following HIV infection with a CD4 ≥500 cells/mm or with AHI (median 
CD4 at diagnosis in this subgroup: 623; IQR 533-760). Among those diagnosed early (CD4 ≥500 cells/mm 
or with AHI), 29% (1,023/3,511) were diagnosed with AHI. Slightly more than half (55%, N = 5,529) of 
persons were diagnosed at <500 cells/mm (median CD4 at diagnosis in this subgroup: 262; 115-378) and 
the remaining 10% did not have a CD4 count reported within 6 months of diagnosis (Table 1).  
Persons diagnosed with HIV in 2012-2015 were young (40% aged 13-29; 25% aged 30-39), male 
(81%), black (42%) or Latino/Hispanic (35%), and men who have sex with men (MSM) (61%) (Table 1). 
Most persons (91%) had any evidence of care (as indicated by a VL or CD4 report) and 75% were 
retained in care (as indicated by ≥2 laboratory reports ≥91 days apart) in the first year of diagnosis 
(Supplemental Table 1).  Compared to persons with a CD4 <500 cells/mm at diagnosis, persons 
diagnosed earlier following HIV infection were more likely to be aged 13-29 (48% versus 33%), white 
(22% versus 16%), and MSM (67% versus 56%). Further details on the clinical characteristics and vital 
status of the cohort can be found in supplemental table 1.  
Median CD4 Counts at Diagnosis and ART Initiation 
From 2012 to 2015, the proportion of persons diagnosed early following HIV infection (i.e., CD4 
≥500 or with AHI) did not change appreciably (35% in 2012 vs. 37% in 2015, p=0.08 in Cochran-
Armitage test for trend). Among persons diagnosed from 2012 to 2015 (i.e., including the AHI cases), the 
median CD4 count at diagnosis remained stable (median CD4 at diagnosis: 381; IQR: 211-568 in 2012 vs. 
390; IQR: 206-553 in 2015, quantile regression coefficient = 2.50 cell increase in median CD4 count per 
year, 95% CI: -3.33-8.33, P = 0.40) (Figure 1). When AHI cases were excluded from the analysis of median 
CD4 counts at diagnosis, the median CD4 count at diagnosis remained stable  (median CD4 at diagnosis: 
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366; IQR: 196-557 in 2012 vs. 372; IQR: 194-565 in 2015, quantile regression coefficient = 1.33 cell 
increase in median CD4 count per year, 95% CI: -4.74-7.41, P=0.66) 
Among persons diagnosed from 2012-2015, the median CD4 at ART initiation was 365 (IQR 200-
538), and the median CD4 count at ART initiation showed a modest but statistically significant increase 
(median CD4 at ART initiation: 354; 195-529 in 2012 and 375; 206-553 in 2015, regression coefficient = 
7.00 cell increase in median CD4 count per year, 95% CI: 1.02-12.98, P=0.02) (Figure 1). When AHI cases 
were excluded from the analysis, the median CD4 count at ART initiation remained stable (median CD4 
at ART initiation: 344; 184-520 in 2012 and 356; 184-540 in 2015, quantile regression coefficient = 5.33 
cell increase in median CD4 count per year, 95% CI: -1.65-7.14, P=0.14).   
Time from Diagnosis to ART Initiation  
The median time from HIV diagnosis to ART initiation was 2.43 months (IQR 1.21-8.66), and PWH 
had a median follow-up time of 3.50 years (IQR 2.5-4.5) (Table 2). Nearly 88% of individuals diagnosed 
from 2012 to 2015 initiated ART as of June 30, 2017. One-quarter of all persons diagnosed from 2012-
2015 initiated ART early (CD4 count >500 cells/mm at ART initiation or ART initiation within 6 months of 
diagnosis for cases known to be an AHI) and 64% of persons diagnosed early initiated ART early.  
Overall, 69% of persons had initiated ART at 6 months post-diagnosis (Table 2 and Figure 2a). The 
time from diagnosis to ART initiation decreased year to year (Table 2 and Figure 2b). Within 6 months of 
diagnosis, 62%, 67%, 72% and 76% of persons diagnosed in 2012, 2013, 2014 and 2015, respectively, 
had initiated ART, with respective median time (months) from diagnosis to ART initiation of 3.34 (IQR: 
1.34-12.75), 2.62(1.28-10.13), 2.16(1.15-7.11), and 2.03(1.11-5.61) (Table 2). Before and after 
adjustment for demographic characteristics, significantly higher rates of ART initiation were observed 
each successive calendar year. The rate of ART initiation was 43% higher in 2015 than in 2012 (adjusted 
Hazards Ratio (HR): 1.43, 95% Confidence Interval: 1.34-1.52) (Table 2).  
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At least 90% of persons who were white or who had a CD4 count at diagnosis of 200-499 cells/mm 
had initiated ART by June 30, 2017 (Supplemental Table 2). Among persons diagnosed in 2015, 77% 
initiated ART within 6 months of diagnosis, and this proportion increased to 87% among persons who 
linked to care within 3 months and represented the subgroup with the highest percentage of persons 
who initiated ART (Supplemental Table 2).   
Year to year reductions in time from diagnosis to ART initiation were observed for all covariate 
subgroups except persons with a CD4 count <200 cells/mm at diagnosis, with 77% initiating ART within 6 
months of diagnosis in 2012 versus 83% initiating ART within 6 months in 2015 (Figure 3a log-rank test 
P=0.39). The largest year to year gains in time to ART initiation were observed among persons aged 13-
29 (in 2012, 56% initiated ART within 6 months versus 75% in 2015, Figure 3b P<0.01), among persons 
diagnosed early (in 2012, 60% initiated ART within 6 months vs 77% in 2015, Figure 3c P<0.01), among 
persons not linked to care within 3 months (in 2012, 23% initiated ART within 6 months vs 43% in 2015, 
Figure 3d P<0.01) or among persons diagnosed at an screening, diagnostic, or referral agency (in 2012, 
54% initiated ART within 6 months vs 80% in 2015, Figure 3e P<0.01).  
DISCUSSION  
We used population-based surveillance data to describe the timing of HIV diagnosis and ART 
initiation among persons with newly diagnosed HIV in the era of universal testing and treatment in a 
major epicenter of the United States HIV epidemic. We observed a slow but steady trend toward earlier 
ART initiation but, importantly, no trend toward earlier diagnosis among PWH diagnosed from 2012 to 
2015. One-third of New Yorkers diagnosed with HIV had a CD4 count >500 cells/mm3 or an AHI at 
diagnosis, and this proportion remained stable from 2012 to 2015, and 77% of persons diagnosed in 
2015 initiated ART within 6 months of diagnosis. These findings suggest local and national 
recommendations for ART initiation upon diagnosis are increasingly being implemented in NYC,26 as the 
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time to ART initiation decreased significantly each year. Nonetheless, ART initiation following HIV 
diagnosis was far from universal or immediate, even in 2015.  
A hallmark of HIV infection is progressive decline of CD4 count in the absence of treatment. 
Therefore, if and when ART is initiated, people diagnosed with a CD4 count <500 cells will necessarily 
initiate ART under the 500 cell-threshold, while reductions in morbidity and mortality occur above this 
threshold.1,2 One-quarter of NYC PWH initiated ART with a CD4 count ≥500 cells/mm. Individual and 
population benefits of early ART initiation will not be fully-realized if the majority of people with HIV are 
diagnosed with CD4<500 cells/mm or if some proportion of persons diagnosed ≥500 cells/mm defer 
treatment initiation. HIV testing initiatives should be tailored to groups with higher frequencies of late 
diagnoses and/or lower testing frequencies to identify people with undiagnosed HIV sooner following 
their infection.30 In this analysis, persons over age 40 or with heterosexual transmission risk were more 
likely to diagnosed with a CD4 count <500 cells. NYC should continue to support outreach for testing 
among persons at high risk for HIV infection. Increasing the rate of HIV testing may be as important as a 
policy as universal treatment.  
Immediate ART will be effective if PWH are willing and able to get HIV tested and seek care.31 The 
2012 expanded treatment guidelines were viewed as more of a public health recommendation (i.e., for 
HIV prevention) than as a clinical recommendation (i.e., for individual health), given that trial data on 
the individual benefits of early ART were not available until 2015.1,2 Adoption of immediate treatment 
recommendations has been gradual, and we may see more rapid ART initiation in more recent years, 
given the focus on early ART for individual health.  
We considered 90% of diagnosed persons initiating ART as a marker of ‘high’ population-level ART 
coverage.6 This threshold was chosen based on the 90-90-90 treatment initiative to end the AIDS 
epidemic, where the goal is that 90% of all diagnosed persons receive sustained ART.6 We observed high 
population-level ART coverage by the end of the study period (i.e., 90% of those diagnosed initiated 
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ART) for whites, persons with a CD4 count at diagnosis that ranged from 200-499 cells/mm, and for 
persons linked to care within 3 months of diagnosis. Notably, we observed lower proportions 
(specifically, less than 90%) initiating ART within 6 months of diagnosis for all other subgroups, even 
after restricting to persons diagnosed in 2015, among whom initiation rates should be high in the 
universal treatment era. PWH diagnosed in 2015 and linked to care within 3 months were closest to 
meeting the target of 90% (87% initiated ART within 6 months). Thus, a gap exists between guidelines, 
which recommend high population ART coverage and initiation as soon as possible after diagnosis for all 
PWH, and the reality of when people start treatment.  
This analysis has several limitations. First, the laboratory-based measure of ART initiation we used is 
a proxy for clinical data on ART use. However, in a validation study, this laboratory-based measure of 
ART aligns with the nadir CD4 count, which is expected to fall prior to- and rise following ART initiation.25  
Second, missing data is caused by migration out of the jurisdiction or not receiving medical care. We 
do not have information on migration, and substantial evidence from New York City and other 
jurisdictions suggests that not accounting for out-migration results in pessimistic surveillance-based care 
measures.32-38 Accounting for outmigration in NYC, improved retention from 63% to 91% in 2012. 32 To 
minimize the potential effect of out-migration, we restricted the analysis to individuals who had at least 
one laboratory event reported to the NYC surveillance registry within 18 months of diagnosis, as these 
individuals were likely to be residing in NYC. Nearly one-quarter of the cohort was not retained in care 
(at least 2 laboratory events at least 90 days apart) in the first year of diagnosis. However, this 
restriction would exclude persons who remain in the city and do not link to care within 18 months.  
Third, deaths prior to ART initiation may be viewed as a competing risk (N = 160 persons had died 
and not initiated ART; 1.6%).39 The results changed minimally when we re-ran the cumulative incidence 
curves with death as a competing risk (e.g., overall 68.5% initiated ART at 6 months when death prior to 
ART initiation was  a competing risk vs. 69.1% when death was censored). Fourth, we assumed that a 
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lower CD4 count indicated a longer time since infection, which may not be true for certain individuals, 
especially persons diagnosed with AHI. To avoid having the AHI cases incorrectly represent more time 
since infection, we present median CD4 counts without the AHI cases and indicators of the timeliness of 
diagnosis and ART initiation which do not rely on CD4: a) the proportion diagnosed early (≥500 cells/mm 
or with AHI) and b) the time from diagnosis to ART initiation.  
Fifth, New York City has a robust infrastructure for HIV care, and results may not generalize to other 
jurisdictions. Sixth, persons who are naturally able to control their VL without treatment (“elite 
controllers”) may be considered to have initiated ART since the algorithm captures those who go from 
detectable to undetectable. However, the population proportion of elite controllers is estimated to be 
small (1% of PWH maintain low to undetectable VL levels without treatment), and any effect of 
mischaracterizing such persons should not change our estimates substantially. Finally, 9.5% of persons 
diagnosed from 2012-2015 were missing a CD4 count within 6 months of diagnosis. This should not 
impact our estimates of ART initiation; however, our estimate of the proportion of persons diagnosed 
early may have been underestimated, given nearly half (49%) of individuals missing CD4 counts were 
aged 13-29, and younger persons were more likely to be diagnosed at higher CD4 counts. Since the 
demographic make-up of persons missing a CD4 count did not change from 2012 to 2015, and the 
proportion missing a CD4 count did not vary by year, we do not expect the trend in proportion of 
persons diagnosed early (i.e., >500) would be affected.   
This analysis examined the timeliness of HIV diagnosis and ART initiation in the universal testing and 
treatment era among PWH diagnosed from 2012 to 2015 in NYC. We observed a slow trend toward 
earlier ART initiation but no trend toward earlier diagnosis. Characterizing the timeliness with which HIV 
diagnosis and ART initiation occur by geographic, demographic and other subgroups can be used to 
inform universal testing and treatment implementation and policy. To realize the full individual and 
population benefits from expanded treatment guidelines, HIV-infected persons need to be diagnosed 
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earlier in the course of infection, underscoring the need for continued efforts to expand and focus HIV 
testing in population groups with historically low testing frequency and high rates of late HIV diagnosis. 
Moreover, continued improvements in rates of timely ART initiation following diagnosis are necessary.   
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TABLES AND FIGURES 
Figure 1. Trends in median CD4 count at diagnosis and ART Initiation and proportion of early 










2a. Overall time to ART initiation 
 
2b. Time to ART initiation by year of diagnosis* 
 




Figure 3. Time to ART Initiation by year of diagnosis, among (a) persons diagnosed with a CD4 count 
<200 cells/mm, (b) persons aged 18-29 years at diagnosis, (c) persons diagnosed early, (d) persons not 
linked to care within 3 months, (e) persons diagnosed at a screening, diagnosis and referral clinic – 
New York City, 2012-2015 
 
Table 1. Characteristics of all Persons Diagnosed with HIV Stratified by CD4 Count at Diagnosis - New 
York City, 2012-2015 
  
Timing of Diagnosis 
 
A. Time to ART Initiation by CD4 count <200 at 
diagnosis, NYC, 2012-2015^ 
 
B. Time to ART initiation by year of diagnosis –among 
persons aged 13-29 at diagnosis* 
 
C. Time to ART initiation by year of diagnosis –among 
persons diagnosed early with CD4 ≥500 cells/mm or 
acute HIV infection* 
 
D. Time to ART initiation by year of diagnosis –among 
persons not linked to care within 3 months* 
 
E. Time to ART initiation by year of diagnosis –among 
persons diagnosed at a screening, diagnosis and 
referral clinic* 
 
 Year of Diagnosis (%) 
Characteristic 2012 2013 2014 2015 
A. CD4 <200 77.07 81.19 80.97 82.60 
B. 13-29 years 56.41 61.97 67.81 74.58 
C. CD4 ≥500 or 
AHI 
59.68 67.19 73.15 76.87 
D. Not linked 
to care 




54.23 60.94 65.33 79.92 
F. Cumulative Proportion with ART Initiation at 6 Months 
Log-rank test: ^p=0.39, *p<0.0001 
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  All diagnoses Early: ≥500 cells/mm 






Total 9,987 (100.00) 3,511 (100.00) 5,529 (100.00) 947 (100.00) 
Age  
   
13 - 29 3,989 (39.94) 1,693 (48.22) 1,826 (33.03) 470 (49.63) 
30 - 39 2,501 (25.04) 877 (24.98) 1,397 (25.27) 227 (23.97) 
40 - 49 1,889 (18.91) 541 (15.41) 1,199 (21.69) 149 (15.73) 
50+ 1,608 (16.10) 400 (11.39) 1,107 (20.02) 101 (10.67) 
Sex at Birth  
   
Male 8,111 (81.22) 2,909 (82.85) 4,405 (79.67) 797 (84.16) 
Female 1,876 (18.78) 602 (17.15) 1,124 (20.33) 150 (15.84) 
Race/Ethnicity  
   
Black  4,118 (41.23) 1,322 (37.65) 2,397 (43.35) 399 (42.13) 
Latino/Hispanic 3,468 (34.73) 1,220 (34.75) 1,922 (34.76) 326 (34.42) 
White 1,834 (18.36) 782 (22.27) 877 (15.86) 175 (18.48) 
Asian Pacific Islander 438 (4.39) 140 (3.99) 270 (4.88) 28 (2.96) 
Other/Unknown 129 (1.29) 47 (1.34) 63 (1.14) 19 (2.01) 
Transmission Risk  
   
Men who have sex with men 6,064 (60.72) 2,366 (67.39) 3,114 (56.32) 584 (61.67) 
Injection drug use 397 (3.98) 161 (4.59) 188 (3.40) 48 (5.07) 
Heterosexual 1,916 (19.18) 580 (16.52) 1,205 (21.79) 131 (13.83) 
Unknown 1,610 (16.12) 404 (11.51) 1,022 (18.48) 184 (19.43) 
Year of Diagnosis  
   
2012 2,616 (26.19) 914 (26.03) 1,441 (26.06) 261 (27.56) 
2013 2,577 (25.80) 862 (24.55) 1,449 (26.21) 266 (28.09) 
2014 2,511 (25.14) 899 (25.61) 1,374 (24.85) 238 (25.13) 
2015 2,283 (22.86) 836 (23.81) 1,265 (22.88) 182 (19.22) 
Median CD4 at Diagnosis (IQR) 382 (208, 564) 623 (533, 760) 262 (115, 378) NA 
Median CD4 at ART (IQR)2 365 (200, 539) 594 (488, 733) 259 (113, 376) 369 (232, 549) 
Timing of ART Initiation3  
   
≥500 cells/mm (early) 2,516 (25.19) 2,240 (63.80) 186 (3.36) 90 (9.50) 
<500 cells/mm 4,910 (49.16) 366 (10.42) 4,322 (78.17) 222 (23.44) 
Missing CD4 1,360 (13.62) 538 (15.32) 491 (8.88) 331 (34.95) 
No ART Initiation 1,201 (12.03) 367 (10.45) 530 (9.59) 304 (32.10) 
NA: Not applicable; IQR: Interquartile Range. Data reported to the NYC HIV Registry as of October 31, 2017. Inclusion Criteria: 
Diagnosed Jan 1, 2012 to Dec 31, 2015, and New York City Residence at Diagnosis.  
(1) These individuals did not link to care or have a CD4 count reported within 6 months 
(2) ART initiation: earlier of a 1-log drop in VL or switch from detectable (>200 copies/µl) to undetectable viral load. CD4 at 
ART initiation is the CD4 count reported closest to and in the 91 days prior to the date of ART initiation 
(3) Early ART initiation defined as ART initiation within 6 months for acute HIV infection or CD4 ≥500 cells/mm at ART initiation 




Table 2. The Time to and Hazards Ratios of ART Initiation1 Stratified by Year of Diagnosis and Timing of 
Diagnosis – New York City, 2012-2015 
 
Supplemental Table 1. Clinical Characteristics of Persons Diagnosed with HIV Stratified by CD4 Count 
at Diagnosis - New York City, 2012-2015  
  
Timing of Diagnosis 
  All diagnoses Early: ≥500 
cells/mm or an 
acute case at 
diagnosis 




Total 9,987 (100.00) 3,511 (100.00) 5,529 (100.00) 947 (100.00) 
Linked within 3 months2     
No 2,369 (23.72) 623 (17.74) 904 (16.35) 842 (88.91) 
Yes 7,618 (76.28) 2,888 (82.26) 4,625 (83.65) 105 (11.09) 
Receipt of Care in the First Year2     
No 893 (8.94) 163 (4.64) 265 (4.79) 465 (49.10) 
Yes 9,094 (91.06) 3,348 (95.36) 5,264 (95.21) 482 (50.90) 
Retained in Care in the Year2     
No 2,470 (24.73) 655 (18.66) 994 (17.98) 821 (86.69) 
Yes 7,517 (75.27) 2,856 (81.34) 4,535 (82.02) 126 (13.31) 
Acute HIV Infection     
No 8,964 (89.76) 2,488 (70.86) 5,529 (100.00) 947 (100.00) 
Yes 1,023 (10.24) 1,023 (29.14) NA NA 
Died during follow-up     
No 9,592 (96.04) 3,451 (98.29) 5,221 (94.43) 920 (97.15) 
Yes 395 (3.96) 60 (1.71) 308 (5.57) 27 (2.85) 
Died prior to ART Initiation 160 (1.60) 17 (0.48) 128 (2.31) 15 (1.58) 
CD4 at Diagnosis3     
Missing 1,046 (10.47) 99 (2.82)  NA 947 (100.00) 
<200 2,142 (21.45) 40 (1.14) 2,102 (38.02) NA 
200 - 350 1,882 (18.84) 186 (5.30) 1,696 (30.67) NA 
Characteristics 








at 6 Months2 




ART at 6 
Months2 
Median time to 
ART initiation – 
Months (25%ile, 
75%ile) 
Unadjusted HR Adjusted HR3 
Total 8,786 (87.97) 69.07 76.31 2.43 (1.21,  8.66)   
Year of Diagnosis       
2012 2,328 (88.99) 61.65 NA 3.34(1.34, 12.75) Ref Ref 
2013 2,263 (87.82) 67.19 NA 2.62 (1.28, 10.13)  1.07 (1.01, 1.14) 1.14 (1.07, 1.21) 
2014 2,205 (87.81) 72.15 NA 2.16 (1.15, 7.11)  1.21 (1.14, 1.28) 1.32 (1.24, 1.39) 
2015 1,990 (87.17) 76.31 76.31 2.03 (1.11, 5.61)  1.30 (1.22, 1.38) 1.43 (1.35, 1.52) 
Timing of 
Diagnosis        
Early: >500 or  
AHI  3,144 (89.55) 69.98 76.87 2.46 (1.21, 8.79) Ref Ref 
<500 4,999 (90.41) 78.25 82.72 1.97 (1.11, 4.89) 1.21 (1.16, 1.27) 1.22 (1.17, 1.28) 
Unknown CD4  
at Diagnosis 643 (67.90) 16.29 29.03 15.87 (7.84, NA) 0.39 (0.36, 0.43) 0.74 (0.67, 0.81) 
Data reported to the NYC HIV Registry as of October 31, 2017 
NA: Not applicable 
(1) ART initiation: earlier of a 1-log drop in VL or switch from detectable (>200 copies/µl) to undetectable viral load. Persons 
contributed observation time from date of diagnosis to ART initiation or were censored at the earlier of death or December 31, 2016 
(2) % of persons initiated ART and the median time to ART initiation based on Kaplan-Meier estimates of months to ART initiation 
(3) Model adjusted for age, sex, race, risk, year of diagnosis, linkage within 3 month, provider type and timing of diagnosis. CD4 at 
diagnosis is not adjusted for due to collinearity with timing of diagnosis 
(4) Persons were considered linked to care if a laboratory (CD4 or VL) event was reported within 8-91 days of diagnosis 
(5) CD4 at diagnosis is the first CD4 count reported within 6 months of diagnosis 
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351 - 499 1,995 (19.98) 264 (7.52) 1,731 (31.31) NA 
≥500 2,922 (29.26) 2,922 (83.22)  NA NA 
Diagnosing Facility     
Outpatient Facility 3,980 (39.85) 1,547 (44.06) 2,171 (39.27) 262 (27.67) 
Inpatient Facility 3,579 (35.84) 1,083 (30.85) 2,344 (42.39) 152 (16.05) 
Screening, Diagnostic, Referral Agency 1,395 (13.97) 605 (17.23) 566 (10.24) 224 (23.65) 
Other/Unknown, Other Specific, Lab 1,033 (10.34) 276 (7.86) 448 (8.10) 309 (32.63) 
CD4 at ART4     
No ART Initiation 1,201 (12.03) 367 (10.45) 530 (9.59) 304 (32.10) 
Missing 1,360 (13.62) 538 (15.32) 491 (8.88) 331 (34.95) 
<200 1,855 (18.57) 64 (1.82) 1,720 (31.11) 71 (7.50) 
200 - 350 1,679 (16.81) 205 (5.84) 1,400 (25.32) 74 (7.81) 
351 - 499 1,689 (16.91) 410 (11.68) 1,202 (21.74) 77 (8.13) 
≥500 2,203 (22.06) 1,927 (54.88) 186 (3.36) 90 (9.50) 
Timing of ART Initiation5     
≥500 cells/mm (early) 2,516 (25.19) 2,240 (63.80) 186 (3.36) 90 (9.50) 
<500 cells/mm 4,910 (49.16) 366 (10.42) 4,322 (78.17) 222 (23.44) 
Missing CD4 1,360 (13.62) 538 (15.32) 491 (8.88) 331 (34.95) 
No ART Initiation 1,201 (12.03) 367 (10.45) 530 (9.59) 304 (32.10) 
NA: Not applicable; IQR: Interquartile Range. Data reported to the NYC HIV Registry as of October 31, 2017. Inclusion Criteria: 
Diagnosed Jan 1, 2012 to Dec 31, 2015, and New York City Residence at Diagnosis.  
(1) These individual did not link to care or have a CD4 count reported within 6 months 
(2) Persons were considered linked to care within 30 days if a laboratory (CD4 or VL) event was reported within 8-91 days of diagnosis. 
Persons were considered to have received care in the first 12 month if a laboratory (CD4 or VL) event was reported within 8-365 days 
of diagnosis. Persons were considered to be retained in care in the 12 months after diagnosis if at least 2 laboratory (CD4 or VL) events 
were reported at least 90 days apart.  
(3) CD4 at diagnosis is the first CD4 count reported within 6 months of diagnosis. Acute HIV cases may have CD4 counts <500 cells/mm 
and included in the early diagnosis column 
(4) ART initiation: earlier of a 1-log drop in VL or switch from detectable (>200 copies/µl) to undetectable viral load. CD4 at ART 
initiation is the CD4 count reported closest to and in the 91 days prior to the date of ART initiation 
(5) Early ART initiation defined as ART initiation within 6 months for acute HIV infection or CD4 ≥500 cells/mm at ART initiation for 
persons diagnosed without acute HIV infection  
 
Supplemental Table 2. The Time to and Hazards Ratios of ART Initiation1 Stratified by Demographic 
and Clinical Characteristics – Among 9,987 Persons Diagnosed with HIV from 2012 to 2015 and 
Residing in New York City  
Characteristics 








ART at 6 
Months2 




ART at 6 
Months2 
Median time to ART 
initiation – Months 
(25%ile, 75%ile) 
Unadjusted HR Adjusted HR3 
Total 8,786 (87.97) 69.07 76.31 2.43 (1.21,  8.66)   
Age       
13 - 29 3,503 (87.82) 64.79 74.58 3.08 (1.38, 11.18) Ref  
30 - 39 2,203 (88.08) 70.69 76.70 2.30 (1.18, 7.93) 1.13 (1.07, 1.19) 1.09 (1.04, 1.16) 
40 - 49 1,673 (88.57) 71.27 76.11 2.10 (1.11, 7.51) 1.19 (1.12, 1.26) 1.15 (1.08, 1.22) 
50+ 1,407 (87.50) 74.28 80.01 2.03  (1.05, 6.03) 1.29 (1.21, 1.37) 1.19 (1.12, 1.28) 
Sex at Birth       
Male 7,128 (87.88) 68.90 76.28 2.46 (1.25, 8.66) Ref Ref 
Female 1,658 (88.38) 69.81 76.47 2.26 (1.15, 8.75) 1.04 (0.99, 1.10) 1.06 (0.97, 1.15) 
Race/Ethnicity       
Black  3,553 (86.28) 65.38 72.57 2.79 (1.25, 10.98) Ref Ref 
Latino/Hispanic 3,080 (88.81) 70.34 78.87 2.39 (1.25, 8.07) 1.10 (1.05, 1.15) 1.11 (1.06, 1.17) 
White 1,657 (90.35) 74.61 80.57 2.00 (1.08, 6.10) 1.26 (1.19, 1.33) 1.32 (1.25, 1.41) 
Asian Pacific Islander 388 (88.58) 74.14 78.68 2.10 (1.28, 6.30) 1.19 (1.07, 1.32) 1.20 (1.08, 1.34) 
Other/Unknown 108 (83.72) 56.59 60.71 4.46 (1.31, 20.56) 0.84 (0.70, 1.02) 0.90 (0.74, 1.08) 
Transmission Risk       
Men who have sex with 
men 5,436 (89.64) 70.73 79.62 2.39 (1.25, 7.57) Ref Ref 
Injection drug use 334 (84.13) 61.76 59.76 3.61 (1.48, 15.77) 0.79 (0.71, 0.89) 0.76 (0.68, 0.86) 
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Heterosexual 1,704 (88.94) 70.45 79.80 2.20 (1.11, 8.69) 1.02 (0.96, 1.07) 0.89 (0.82, 0.97) 
Unknown 1,312 (81.49) 62.88 63.52 2.95 (1.21, 14.07) 0.83 (0.79, 0.89) 0.86 (0.81, 0.92) 
Linked within 3 months4       
No 1,673 (70.62) 36.76 51.70 8.49 (4.39, 19.34) Ref 0.50 (0.47, 0.53) 
Yes 7,113 (93.37) 80.80 86.63 1.74 (1.02, 4.07) 2.29 (2.17, 2.42) 1.98 (1.87, 2.11) 
CD4 at Diagnosis5       
Missing 702 (67.11) 17.67 30.15 15.77 (7.57, NA) 0.41 (0.37, 0.44)  
<200 1,912 (89.26) 80.37 82.60 1.54 (0.92, 4.23)  1.44 (1.36, 1.53)  
200 - 350 1,731 (91.98) 80.67 86.17 1.93 (1.15, 4.39) 1.30 (1.23, 1.38)  
351 - 499 1,815 (90.98) 75.17 79.82 2.26 (1.28, 5.93) 1.13 (1.06, 1.20)  
≥500 2,626 (89.87) 67.66 77.11 2.66 (1.28, 9.48)  Ref  
Provider Type       
Outpatient Facility 3,564 (89.55) 72.42 77.58 2.30 (1.28, 7.05) Ref Ref 
Inpatient Facility 3,122 (87.23) 73.18 77.17 1.74 (0.95, 7.05) 1.08 (1.03, 1.14) 1.23 (1.17, 1.29) 
Screening, Diagnostic,      
Referral  1,209 (86.67) 63.27 79.92 3.25 (1.70, 11.77) 0.80 (0.75, 0.85) 1.00 (0.93, 1.06) 
Other/Unknown Lab 891 (86.25) 52.25 64.87 5.61 (1.84, 14.10) 0.70 (0.65, 0.75) 0.96 (0.89, 1.03) 
Timing of Diagnosis        
Early: >500 or AHI  3,144 (89.55) 69.98 76.87 2.46 (1.21, 8.79) Ref Ref 
<500 4,999 (90.41) 78.25 82.72 1.97 (1.11, 4.89) 1.21 (1.16, 1.27) 1.22 (1.17, 1.28) 
Unknown CD4 at 
Diagnosis 643 (67.90) 16.29 29.03 15.87 (7.84, NA) 0.39 (0.36, 0.43) 0.74 (0.67, 0.81) 
Data reported to the NYC HIV Registry as of October 31, 2017. Inclusion Criteria: Diagnosed Jan 1, 2012 to Dec 31, 2015, and New York City 
Residence at Diagnosis. 
(1) ART initiation: earlier of a 1-log drop in VL or switch from detectable (>200 copies/µl) to undetectable viral load. Persons contributed 
observation time from date of diagnosis to ART initiation or were censored at the earlier of death or December 31, 2016 
(2) % of persons initiated ART and the median time to ART initiation based on Kaplan-Meier estimates of months to ART initiation 
(3) Model adjusted for age, sex, race, risk, year of diagnosis, linkage within 3 month, provider type and timing of diagnosis. CD4 at diagnosis is not 
adjusted for due to collinearity with timing of diagnosis 
(4) Persons were considered linked to care if a laboratory (CD4 or VL) event was reported within 8-91 days of diagnosis 




CHAPTER 3: QUANTIFYING DIAGNOSIS DELAY FOLLOWING HIV 
SEROCONVERSION: ASSESSING THE LINEARITY ASSUMPTION OF CD4 
DECLINE (AIM 2A) 
ABSTRACT 
Background: One approach to estimating the timing of HIV seroconversion relative to diagnosis is to 
model time since seroconversion based on CD4 decline. An assumption of the CD4 decline approach is 
that the square root of the CD4 cell count decreases linearly over time prior to antiretroviral treatment 
(ART) initiation. If the assumption is true, then utilizing CD4 counts reported at any point in the pre-ART 
period would result in estimates of diagnosis delay that are not appreciably different.   
Methods: Applying CD4 depletion model parameters from seroconverter cohort data to New York City 
residents, we compared the time from seroconversion to diagnosis (diagnosis delay) as estimated 
according to the square root of the first or second pre-ART CD4 count. 
Results: Among 12,849 NYC residents who were diagnosed with HIV from 2006 to 2015 with at least 2 
pre-ART CD4 count measurements around time of diagnosis, the average diagnosis delays based on the 
first or second pre-ART CD4 count were similar (4.93 years (95% Confidence intervals (CI):4.84-5.03) and 
4.85 years (95% CI:4.76-4.95), respectively, p-value=0.09, Wilcoxon signed-rank). Among the subset of 
people whose second pre-ART CD4 count was measured >6 months after diagnosis (N=2,761), the 
average diagnosis delay based on first pre-ART CD4 count was shorter (3.52 years, 95% CI:3.35-3.68) 
than the second pre-ART CD4 count (3.94 years, 95% CI:3.77-4.12) but not significantly (p-value=0.115). 
Conclusions:  Our results are consistent with the linearity assumption of the CD4 depletion model. 
Researchers and implementers may use only one pre-ART CD4 count, including those reported more 





In the era of universal test and treat, an estimate of the infectious period from HIV seroconversion 
to ART initiation could become a priority indicator to identify and monitor whether HIV testing and 
prevention initiatives are successfully reducing the infectious period.1-3 Yet, HIV seroconversion is almost 
always an unobserved event. Inferring a date of seroconversion is difficult because a minority of persons 
are diagnosed during primary or acute HIV infection, the first stage of HIV-infection.4 Rather, most 
persons are diagnosed in the later stages of HIV infection when the duration of the infection is much less 
certain.  
One approach to estimating HIV seroconversion and the duration of infection is based on CD4 
decline.5 The underlying assumption of the CD4 decline approach is that among ART-naïve people, the 
square root of the CD4 cell count decreases over time6, and the time since seroconversion can be 
inferred by applying an estimated rate of CD4 decline (from a European seroconverter cohort) to a 
population with pre-ART CD4 count.5,7-9 This approach has been used to estimate diagnosis delays (time 
from seroconversion to HIV diagnosis) locally and nationally.5,7,8,10 However, estimated delays in 
diagnosis rely on the accuracy of the initial CD4 depletion model, which assumes the mean square root 
of CD4 count is linearly related to the time since seroconversion. Some evidence suggests the rate—
square root transformed—of CD4 decline over time is nonlinear.11  
Using data from NYC, we compared estimated delays in diagnosis based on the first or second pre-
ART CD4 count reported to HIV surveillance among people with at least two pre-ART CD4 counts. We 
hypothesized that estimates of diagnosis delays based on the first or the second CD4 count would not 
be appreciably different from one another, if the mean square root of CD4 count is linearly related to 
the time since infection at the population level.  
METHODS 
Data source and population 
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The NYC Department of Health and Mental Hygiene has conducted population-based, name-based 
AIDS surveillance since 1981 and HIV surveillance since 2000.12 Electronic reporting of all HIV-related 
laboratory tests (including viral load (VL) and CD4), has been mandatory since 2005.13  
This analysis included 32,556 people diagnosed with HIV in NYC from 2006 to 2015 and aged >13 years 
at HIV diagnosis, with their laboratory information reported through June 30, 2017. We excluded people 
who did not have at least one VL or CD4 test reported to the Registry within 18 months of diagnosis 
(N=4,394 excluded, leaving N=28,162 in analytic cohort), as people without a VL or CD4 for 18 months 
either were not receiving HIV medical care within NYC or moved out of NYC.   
Approximately 20% (5,527/28,162) of all people in the 2006-2015 analytic cohort have an unknown 
HIV transmission risk factor in the surveillance registry. Following Centers for Disease Control and 
Prevention (CDC) guidance, we used sex-stratified multiple imputation procedures to assign these 
people a transmission risk category.5,14 Data were imputed 10 times both for males and females. We 
combined results from the datasets to generate an overall probability weight for transmission risk 
category (e.g., an individual could have a weight of 0.7 for heterosexual and 0.3 for injection drug use 
transmission risk, respectively).  
We restricted the dataset to people who had at least two pre-ART CD4 counts reported (analytic 
cohort N = 12,849) and restricted the analytic cohort to people with >6 months between the two pre-
ART CD4 counts (subset N= 2,761) 
Definitions  
ART initiation 
ART initiation was defined based on the earlier occurrence of either: a ≥1-log drop in detectable VL 
(defined as ≥200 copies/mL) over a 3-month period or a detectable VL followed by an undetectable VL 
(defined as <200 copies/mL).15,16 The date of probable ART initiation was the mid-point between the two 
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VL occurrences. If the first VL reported to the Registry was undetectable, then the estimated date of ART 
initiation was the mid-point between diagnosis and the first undetectable VL.  
First or second pre-ART CD4 Count 
The first and second pre-ART CD4 counts had to be measured prior to the estimated date of ART 
initiation. The first pre-ART CD4 count was the first pre-ART CD4 count reported within 6 months of 
diagnosis. The 6-month rule was applied to help ensure we excluded post-treatment CD4 counts, given 
we used a proxy for treatment initiation. The second pre-ART CD4 count was the second CD4 count 
reported after diagnosis and following the first pre-treatment CD4 count, and no restriction on the 
timing of the CD4 count relative to diagnosis was applied.  
Time from seroconversion to pre-ART CD4 count 
 To estimate the date of seroconversion, we applied an estimated rate of CD4 decline, which was 
based on previously published estimates from the CASCADE seroconverter cohort, to the NYC 
population, people diagnosed with HIV from 2006 to 2015 and having at least two pre-ART CD4 counts.5  
 The CD4 depletion model relates the square root of the first pre-ART CD4 count (CD4t) to time of 
infection through a linear mixed model.6,17 
 
Where t is the time from HIV seroconversion to the date of the first pre-ART CD4 count, CD4t is the first 
pre-ART CD4 count, and the intercept (a0) and the slope (b1) are random variables following a normal 
distribution.  
 The duration of infection (t) is then estimated for an individual by Formula 2, using the previously 
published model parameters.  
𝐹𝑜𝑟𝑚𝑢𝑙𝑎 2: 𝑇𝑖 = (√𝐶𝐷4 −  𝑎0 − 𝑒1𝑡)/ 𝑏1 
For Formula 2, the intercept a and slope b, for each person, were assumed to follow a bivariate 
normal distribution N [(a,b), (standard errora, standard errorb), correlation coefficient(p)].  
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 The mean intercept and slope, standard errors and correlation coefficient were based on published 
estimates for combinations of sex at birth, age group at seroconversion and risk group from the 
CASCADE cohort (see Song, et al 2016).5 Since the age group at seroconversion is unknown in our 
population, we used the age at diagnosis as an initial approximation of the age at seroconversion and 
estimated T using age at diagnosis, (Formula 2). We then used T to estimate age at seroconversion 
(Formula 3, below). 44% of the cohort was assigned an age group at seroconversion that was earlier 
than their age group at diagnosis, and the remaining 56% stayed in the same age group. Lastly, we re-
estimated T using the new estimated age at seroconversion (Formula 2).   
 Age at seroconversion is estimated as  
 
 Finally, the date of seroconversion is then estimated by: 
 
 In instances where seroconversion was estimated to occur after diagnosis, the date of 
seroconversion was set to the date of diagnosis. For people diagnosed with acute HIV infection, the date 
of seroconversion was assigned as the date of diagnosis.  
 Assuming normal distributions and with sex-, age- and risk-specific standard errors described in Song 
et al5 and above in Formulas 1 and 2, we estimated the duration (Ti from seroconversion to first pre-ART 
CD4 count) for each person 1,000 times and took the average to infer an individual’s date of 
seroconversion and incorporate variance. We repeated this process using the second pre-ART CD4 
count. 
Diagnosis delay 
 We calculated two estimates of diagnosis delay as the difference between the date of diagnosis and 




We generated mean and median years since seroconversion overall and by transmission or 
demographic subgroups. Using the Wilcoxon signed-rank test, to compare repeated measurements on a 
sample, we compared the distribution of diagnosis delay based on the first pre-ART CD4 count with 
estimates of the diagnosis delay based on the second pre-ART CD4 count. We compared estimates of 
diagnosis delay based on the first or second pre-ART CD4 count among the entire population and 
repeated the comparison in a subset of individuals who had their second CD4 count reported >6 months 
after diagnosis.  
We used weighted procedures to handle the imputation weights. All analyses were conducted in 
SAS version 9.4 (SAS Institute, Cary, N.C.).  
This study was approved by the institutional review boards at The City University of New York School 
of Public Health and the New York City Department of Health and Mental Hygiene. For these secondary 
data analyses, we received a waiver for informed consent under 45 CFR 46.116(d)(2). 
RESULTS 
 The analysis included 12,849 NYC residents who were diagnosed with HIV in NYC from 2006 to 2015 
and had at least two pre-ART CD4 counts. The cohort was predominately male (77%), black or 
Latino/Hispanic (79%), and young (62% aged <40 years at diagnosis). The subset of people who had a 
second CD4 count reported >6 months after diagnosis (N =2,761) was similar to the whole analytic 
cohort (N = 12,849) in terms of demographics (i.e., mostly male, black or Latino/Hispanic and young).  
 Among the entire cohort (N=12,849), the first pre-ART CD4 count tended to be slightly higher 
(median 400 cells/µL, interquartile range (IQR): 222-575) than the second pre-ART CD4 count (388 
cells/µL, IQR:218-563). By design, all people had the first pre-ART CD4 within 6 months of diagnosis 
(median: 13 days, IQR: 136-145), and the second pre-ART CD4 was a median of 87 days (IQR:33-163) 
after diagnosis. The subset with a second pre-ART CD4 count >6 months after diagnosis, had higher first 
and second CD4 counts than the overall cohort, and the median time from diagnosis to the first or the 
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second pre-ART CD4 count was 28 days (IQR:8-79, with 100% in the first 6 months of diagnosis) and 300 
days (IQR:224-553), respectively. 
Years from seroconversion to diagnosis  
 Among the entire cohort, estimates of the average diagnosis delays based on the first and second 
pre-ART CD4 count were similar (4.93 years (95% Confidence intervals (CI):4.84-5.03) and 4.85 years 
(95% CI:4.76-4.95), respectively) (p-value for Wilcoxon test 0.09) (Table 2). We observed non-significant 
differences in diagnosis delay based on first or second CD4 count across all subgroups except for men 
(first: 4.82, 95% CI: 4.72-4.92 and second: 4.72, 95% CI: 4.62-4.82, p-value=0.040) and for men who have 
sex with men (first: 4.48 95% CI: 4.68-5.00 and second: 4.37, 95% CI: 4.25-4.48, p-value=0.038).   
 Amongst the subset of people who had their second pre-ART CD4 count measurement >6 months 
after diagnosis, the diagnosis delays based on first pre-ART CD4 count were shorter (3.52 years, 95% CI: 
3.35-3.68) than delays based on the second pre-ART CD4 count (3.94 years, 95% CI: 3.77-4.12), although 
the difference was non-significant (p-value=0.115). We observed non-significant differences in diagnosis 
delay based on first or second CD4 count across all subgroups except for women (first: 3.56 years, 95% 
CI:3.16-3.95 and second: 4.31, 95% CI:3.84-4.75, p-value=0.027) and persons with heterosexual 
transmission risk (first: 3.82 years, 95% CI:3.50-4.15 and second: 4.65, 95% CI:4.29-5.01, p-value=0.025).  
 Figure 1 shows density plots for diagnosis delays based on first or second pre-ART CD4 count among 
the entire cohort (panel A) and the subset (panel B). Using the second pre-ART CD4 count resulted in 
5,320 people (or 41% of the 12,849 cohort) with a shorter estimated delay (delay closer to value of 0) 
than the first pre-ART CD4 count (panel A). Among the 5,320 people with a shorter delay based on the 
second versus first pre-ART CD4 count, the second pre-ART CD4 count had a median value higher than 
the first pre-ART CD4 count (second CD4 count: 351 cells/µL versus first CD4 count: 278 cells/µL, 
difference of 73 cells). Among the subset of people who had a second pre-ART CD4 count reported >6 
months after diagnosis, the second pre-ART CD4 count resulted in 916 people (or 33% of the 2,761 
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subset) with a shorter estimated delay (delay closer to value of 0) than the second pre-ART CD4 count 
(panel B), and the second pre-ART CD4 count had a median value higher than the first pre-ART CD4 
count (385 versus 310 cells/µL, difference of 75 cells).  
DISCUSSION 
Voluntary HIV testing followed by immediate ART initiation (universal testing and treatment) has 
become an integral part of local and global strategies to eliminate HIV and control the HIV/AIDS 
epidemic.18-26 Minimizing the time from HIV infection to ART initiation is essential for universal test and 
treatment to be optimally effective. However, neither frontline implementers, nor health agencies or 
researchers have typically focused on quantifying the HIV-infectiousness period, partially due to the 
absence of population-based data on the timing of seroconversion.3 We used a CD4 decline model to 
estimate years since seroconversion among NYC residents with at least two pre-ART CD4 counts.5 An 
assumption of the CD4 decline model is that the square root of the CD4 cell count decreases linearly 
over time. If the assumption is valid, then we should estimate similar lengths of diagnosis delay utilizing 
CD4 counts reported at any point in the pre-ART period.  We found that average diagnosis delay did not 
vary meaningfully between estimates based on the first or second pre-ART CD4 count in the overall 
cohort (4.93 years versus 4.85 years, respectively) or in the subset, people with a second CD4 count 
reported >6 months after diagnosis (3.52 years versus 3.94 years, respectively). Our results are 
consistent with the linearity assumption of the square root CD4 depletion model. Researchers and 
implementers may use only one pre-ART CD4 count, including those reported more than 6 months after 
diagnosis, to estimate diagnosis delay at the population-level. 
We estimated diagnosis delay among the subset of people with a second CD4 count reported >6 
months after diagnosis, as estimates were based on a second pre-ART CD4 count that was lower and 
more remote (relative to date of diagnosis and seroconversion) than the first pre-ART CD4 count. The 
later and generally lower second pretreatment CD4 counts contributed to longer estimates of diagnosis 
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delay, as estimates of delay based on the second pre-ART CD4 count were slightly longer, albeit non-
significantly, than estimates based on the first pre-ART CD4 count. The Centers for Disease Control and 
Prevention recommends HIV surveillance jurisdictions use the first CD4 count reported within 3 months 
of diagnosis for inferring time since seroconversion, as this restriction ensure that post-treatment CD4 
counts are excluded.5 Our analysis suggest that researchers could validly use CD4 counts reported much 
later than 3 months following diagnosis, assuming they have an actual or proxy date of initial treatment 
following diagnosis to restrict to the pre-ART CD4 counts.  
As expected, given progressive decline of CD4 count in the absence of treatment, the first pre-ART 
CD4 count had a median value higher than the second pre-ART CD4 count in the overall cohort (first CD4 
count: 400 versus second CD4 count: 388, difference of 12 cells). While estimated delays based on first 
or second pre-ART CD4 count were not materially different, the estimates based on the first pre-ART 
count were longer than the second pre-ART CD4 count in the overall analytic cohort but not in the 
subset with a second CD4 count reported >6 months after diagnosis. The shorter estimated values based 
on second pre-ART CD4 count were due to a large proportion of people (41% of the cohort) with a 
higher second versus first pre-ART CD4 counts and likely occurred for two reasons. First, our proxy 
metric of ART initiation may have incorrectly attributed some post-treatment CD4 measures to the pre-
ART period. Second, CD4 measurements at the individual level have been shown to be highly variable 
due to factors such as smoking, menstruation, physical exercise, measurement error and 
comorbidities.27-29  
The following limitations apply. First, we have shown that CD4 counts at different points in the pre-
ART period result in similar estimates of diagnosis delay, but the accuracy of these estimates in a given 
population depends on the accuracy of the CD4 depletion model parameters. The CD4 decline 
parameters assume no changes in virulence of HIV strains over time, which, if present in NYC, could alter 
the average rates of CD4 decline in the population. Future research should attempt to validate 
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estimated diagnosis delay based on CD4 counts, perhaps among people with HIV intertest intervals 
documented in medical records or in more recent seroconverter cohorts. Second, we tested for 
differences in diagnosis delay based on the first or second pre-ART CD4 count. Findings consistent with 
the null hypothesis could mean either that there was no significant difference in estimated delay based 
on first or second pre-ART CD4 counts or that the analysis was underpowered to observe a difference. In 
the smaller subset (N =2,761), we may have been underpowered to observe a difference, particularly in 
subgroups. Finally, our approach provides evidence that the decline between the first and second pre-
ART CD4 counts in this cohort was likely linear but does not give evidence about the period prior to the 
first pre-treatment CD4 count. However, excluding the acute phase of infection, we do not have reason 
to expect the shape of decline prior to the first pre-ART CD4 count would be different than the shape of 
decline between the first and second pre-ART CD4 counts.  
 Estimating diagnosis delays is important for monitoring and tracking progress of universal test and 
treat strategies and efforts aimed at ending the HIV/AIDS epidemic. We used a CD4 decline model to 
estimate years since seroconversion among NYC residents with at least two pre-ART CD4 counts.5 This 
approach assumes the mean square root of CD4 count is linearly related to the time since infection. We 
found that average diagnosis delay did not vary between estimates based on the first or second pre-ART 
CD4 count, and average diagnosis delay did not vary when the first and second pre-ART CD4 values were 
separated even by an average of 15 months. These results suggest that parameter estimates based on 
the linear assumption may be valid for population-level estimation of diagnosis delay and that pre-ART 
CD4 counts reported more than 6 months after diagnosis may be used to infer time since 
seroconversion. 
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TABLES AND FIGURES 
Figure 1. Diagnosis delay based on first or second pre-treatment CD4 amongst entire persons 
diagnosed from 2006 to 2015 (A) or amongst people diagnosed from 2006 to 2015 and having a 





Table 1. Characteristics of people diagnosed with HIV from 2006 to 2015 and having at least two pre-
treatment CD4 counts – New York City 
 
Characteristics  People with ≥2 Pre-Treatment CD4 Counts People with Second CD4 >6 Months After 
Diagnosis  








Total 12,849 (100.00) 400 (222, 575) 388 (213, 563) 2,761 (100.0) 454 (301, 625) 399 (229, 565) 
Sex 
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 Male 9,914 (77.16) 402 (232, 570) 392 (225, 561) 2,122 (76.86) 453 (303, 614) 401 (235, 562) 
 Female 2,935 (22.84) 388 (187, 593) 371 (181, 571) 639 (23.14) 458 (287, 656) 393 (200, 574) 
Race/Ethnicity 
      
 Black 5,912 (46.01) 378 (194, 554) 362 (180, 536) 1,428 (51.72) 433 (277, 598) 378 (201, 548) 
 Latino/Hispanic 4,220 (32.84) 406 (229, 574) 391 (220, 561) 893 (32.34) 459 (310, 627) 402 (235, 558) 
 White 2,225 (17.32) 453 (296, 624) 452 (301, 623) 363 (13.15) 537 (387, 725) 471 (310, 646) 
 Asian/Pacific  
Islander 
401 (3.12) 369 (222, 552) 387 (227, 549) 54 (1.96) 484 (301, 660) 417 (290, 542) 
 Other/Unknown 91 (0.71) 418 (226, 626) 394 (226, 598) 23 (0.83) 423 (216, 614) 356 (170, 503) 
Age at Diagnosis 
      
 13 - 29 4,670 (36.35) 446 (308, 602) 431 (299, 587) 1,197 (43.35) 481 (333, 620) 418 (270, 568) 
 30 - 39 3,288 (25.59) 406 (230, 577) 399 (226, 568) 670 (24.27) 461 (329, 626) 406 (243, 567) 
 40 - 49 2,944 (22.91) 360 (148, 565) 351 (142, 553) 555 (20.10) 431 (245, 644) 370 (161, 569) 
 50+ 1,947 (15.15) 283 (86, 483) 278 (89, 482) 339 (12.28) 397 (220, 597) 328 (181, 529) 
Transmission Risk 
(Imputed) 
      
 Male sexual  
contact (MSM) 
7,998 (62.24) 419 (268, 582) 411 (260, 576) 1,677 (60.75) 467 (325, 622) 411 (261, 571) 
 Injection drug  
use (IDU) 
720 (5.61) 327 (113, 544) 312 (112, 518) 185 (6.71) 424 (234, 616) 351 (190, 526) 
 MSM & IDU 287 (2.23) 437 (258, 645) 417 (261, 576) 78 (2.83) 498 (307, 659) 467 (296, 587) 
 Heterosexual  
contact 




Table 2. Estimates of diagnosis delay based on first or second pre-treatment CD4 amongst the entire cohort of people diagnosed with HIV 
from 2006 to 2015 overall (a) and restricted to people having a second CD4 count reported >6 months following diagnosis– New York City 
 People with ≥2 Pre-Treatment CD4 Counts (N = 12,849) People with Second CD4 >6 Months After Diagnosis (N = 2,761)  
First CD4  Second CD4 Wilcoxon First CD4 Second CD4  Wilcoxon  
Median Mean 95% Median Mean 95% P-value Median Mean 95% Median Mean 95% P-value 
Total 2.81 4.93 (4.84, 5.03) 2.75 4.85 (4.76, 4.95) 0.09 1.46 3.52 (3.35, 3.68) 1.69 3.94 (3.77, 4.12) 0.12 
Sex 
     
     
 Male 2.83 4.82 (4.72, 4.92 ) 2.71 4.72 (4.62, 4.82 ) 0.04 1.52 3.50 (3.33, 3.68 ) 1.75 3.83 (3.64, 4.02 ) 0.62 
 Female 2.73 5.32 (5.10, 5.54 ) 2.86 5.32 (5.10, 5.54 ) 0.98 1.07 3.56 (3.16, 3.95 ) 1.55 4.31 (3.87, 4.75 ) 0.03 
Race/Ethnicity 
     
     
 Black 3.35 5.43 (5.29, 5.57 ) 3.32 5.39 (5.25, 5.53 ) 0.62 1.93 3.89 (3.66, 4.12 ) 2.11 4.33 (4.08, 4.58 ) 0.41 
 Latino/Hispanic 2.77 4.84 (4.68, 5.00 ) 2.81 4.80 (4.64, 4.96 ) 0.53 1.41 3.40 (3.13, 3.68 ) 1.72 3.90 (3.59, 4.20 ) 0.12 
 White 1.61 3.74 (3.54, 3.94 ) 1.40 3.55 (3.36, 3.75 ) 0.06 0.00 2.26 (1.87, 2.65 ) 0.00 2.61 (2.20, 3.03 ) 0.56 
 Asian/Pacific Islander 3.74 5.20 (4.69, 5.72 ) 2.90 4.76 (4.25, 5.27 ) 0.16 1.05 3.34 (2.13, 4.54 ) 0.69 2.86 (1.72, 4.00 ) 0.82 
 Other/Unknown 2.43 5.09 (3.87, 6.31 ) 2.30 4.79 (3.66, 5.91 ) 0.66 2.30 5.05 (2.77, 7.34 ) 3.35 5.17 (3.27, 7.07 ) 0.90 
Age at Diagnosis 
     
     
 13 - 29 2.23 3.90 (3.77, 4.04 ) 2.22 3.90 (3.77, 4.04 ) 0.43 1.28 3.38 (3.13, 3.63 ) 1.75 3.83 (3.56, 4.11 ) 0.16 
 30 - 39 2.59 5.10 (4.89, 5.30 ) 2.36 4.99 (4.79, 5.20 ) 0.20 1.32 3.39 (3.04, 3.74 ) 1.30 3.98 (3.59, 4.37 ) 0.43 
 40 - 49 3.26 5.61 (5.41, 5.80 ) 3.07 5.50 (5.30, 5.69 ) 0.54 1.65 3.81 (3.45, 4.17 ) 1.85 4.27 (3.88, 4.66 ) 0.41 
 50+ 4.38 6.12 (5.90, 6.33 ) 4.24 5.93 (5.72, 6.14 ) 0.38 1.93 3.74 (3.35, 4.13 ) 2.04 3.72 (3.33, 4.11 ) 0.56 
Transmission Risk (Imputed) 
     
     
 Male sexual contact (MSM) 2.61 4.48 (4.36, 4.59 ) 2.45 4.37 (4.25, 4.48 ) 0.04 1.50 3.43 (3.22, 3.65 ) 1.72 3.76 (3.53, 3.99 ) 0.48 
 Injection drug use (IDU) 3.46 4.81 (4.57, 5.06 ) 3.32 4.65 (4.42, 4.89 ) 0.75 1.82 3.31 (2.89, 3.72 ) 1.78 3.18 (2.79, 3.58 ) 0.86 
 MSM & IDU 1.88 3.45 (3.13, 3.77 ) 1.69 3.32 (3.00, 3.64 ) 0.67 0.60 2.52 (2.01, 3.03 ) 0.00 2.17 (1.64, 2.70 ) 0.21 




CHAPTER 4: ESTIMATES OF THE DURATION OF HIV INFECTIOUSNESS 
AMONG PEOPLE NEWLY DIAGNOSED WITH HIV FROM 2006 TO 2015, 
NEW YORK CITY (AIM 3) 
ABSTRACT 
Background: We estimated the time from HIV seroconversion to ART initiation in a population-based 
sample of people diagnosed with HIV during an era of expanding HIV testing and treatment efforts.  
Methods: Applying CD4 depletion model parameters from seroconverter cohort data to our population-
based sample, we related the square root of the first pre-treatment CD4 count to time of serconversion 
though a linear mixed model and estimated the time from seroconversion to diagnosis and ART 
initiation.  
Results: Among 28,162 people diagnosed with HIV during 2006-2015, 89% initiated ART by June 2017. 
The median CD4 count at diagnosis increased from 326 (Interquartile range (IQR):132-504) to 390 
(IQR:216-571) cells/µL from 2006-2015. The average time from estimated seroconversion to ART 
initiation decreased by 33% from 8.0 years (95% confidence interval [CI]:7.8-8.2) in 2006 to 5.4 years 
(95%CI: 5.1-5.6) in 2015. Contributing to the reduction in time to ART initiation, the average time from 
estimated seroconversion to diagnosis decreased by 22%, from 6.5 years (95% CI:6.3-6.7) to 5.1 years 
(95% CI:4.9-5.4) from 2006-2015, and the average time from diagnosis to ART initiation reduced by 87%, 
from 1.5 years (95% CI:1.4-1.5) to 0.2 years (95% CI:0.2-0.3) from 2006-2015. 
Conclusions:  The estimated time from seroconversion to ART initiation was reduced in tandem with 
expanded HIV testing and treatment efforts. While the time from diagnosis to ART initiation decreased 
from 1.5 to 0.2 years, the time from seroconversion to diagnosis was 5.0 years among people diagnosed 




To end HIV/AIDS as a public health threat, we must minimize the time from infection to treatment 
(i.e., the infectious period) and support the achievement of early and sustained viral suppression, 
thereby decreasing HIV-related morbidity and mortality and preventing onward spread of HIV.1-4 The 
achievement of timely viral suppression requires prompt testing and diagnosis following HIV 
seroconversion—typically an unobservable event—and timely initiation of antiretroviral treatment 
(ART). It is critical, therefore, to better understand and monitor treatment and diagnosis delays 
following seroconversion.5 
Generally, researchers assess the timeliness of HIV diagnosis and ART initiation by examining the 
distribution of CD4 counts at diagnosis and ART initiation, respectively, or with static measures (e.g., the 
proportion of people who initiate ART).6,7 In New York City (NYC), an epicenter of the HIV epidemic, 
increases in CD4 counts at diagnosis and ART initiation suggest a trend toward earlier diagnosis and 
treatment initiation.6,7 Yet, in 2015 more than one in six (17%) NYC residents newly diagnosed with HIV 
were diagnosed late (i.e., AIDS diagnosis within 30 days of HIV diagnosis), and one-quarter of NYC 
residents who were diagnosed with HIV in 2015 had not initiated ART as of 6 months post-diagnosis.6,8  
In New York City, the ‘treat all’ recommendation, immediate treatment for all people diagnosed 
with HIV, has existed since late 2011, and efforts to ‘treat all’ were contemporaneous with large scale 
HIV testing initiatives in NYC.9-11 Yet, commonly used metrics (e.g., the HIV care cascade or median CD4 
counts) provide an incomplete picture of subsequent progress towards ‘treat all’, as they do not give 
information on the amount of time that passes between infection and diagnosis and ART initiation.5,12 
We estimated the elapsed time from seroconversion to diagnosis and to ART initiation to quantify the 
infectious period of HIV at the population level in NYC before and after the ‘treat all’ recommendation.  
METHODS 
Data source and population 
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The NYC Department of Health and Mental Hygiene has conducted population-based, name-based 
AIDS surveillance since 1981 and HIV surveillance since 2000.13 Electronic reporting of all HIV-related 
laboratory tests (including viral load (VL) and CD4), has been mandatory since 2005.14 CD4 counts and VL 
reported to surveillance are considered reliable indicators of HIV medical care receipt.15  
This analysis included people diagnosed with HIV from 2006 to 2015 and aged >13 years at HIV 
diagnosis with their laboratory information reported through June 30, 2017 (N=32,556). We excluded 
people who did not have at least one VL or CD4 test reported to the Registry within 18 months of 
diagnosis (N=4,394 excluded, leaving N=28,162 in analytic cohort), as people without a VL or CD4 for 18 
months either moved out of NYC or were not receiving HIV medical care within NYC.   
Approximately 20% (5,527/28,162) of all people diagnosed from 2006 to 2015 were reported as 
having an unknown transmission risk factor. Following Centers for Disease Control and Prevention 
guidance, we used sex-stratified multiple imputation procedures to assign these people a transmission 
risk category and assigned an individual a weight based on imputed transmission risk categories.16,17 
Data were imputed 10 times both for males and females. We combined results from the datasets to 
generate an overall probability weight for transmission risk category. For example, if 7 models imputed 
heterosexual transmission risk and 3 imputed injection drug use for an individual with an unknown 
transmission risk category, that individual was assigned two weights of 0.7 for heterosexual and 0.3 for 
injections drug use transmission risk factors, respectively. 
To account for people without a pre-treatment CD4 count result (16% of the sample: 4,624/28,162), 
we assigned a weight to people with a pre-treatment CD4 count. The weight was the reciprocal of the 
proportion of cases with a CD4 test in each stratum, where strata were a combination of sex, 
transmission risk category (known or imputed), age at diagnosis, year of diagnosis, race/ethnicity or 
clinical status (AIDS diagnosis) as of June 30, 2017. The final weight was the product of the transmission 





ART initiation was defined based on the earlier occurrence of either: a ≥1-log drop in detectable VL 
(defined as ≥200 copies/mL) over a 3-month period or a detectable VL followed by an undetectable VL 
(defined as <200 copies/mL).7,18 The estimated date of ART initiation was the mid-point between the 
two VLs occurrences. If the first VL reported to the Registry was undetectable, then the estimated date 
of ART initiation was the mid-point between diagnosis and the undetectable VL.  
Viral suppression 
 Viral suppression was defined as the last VL in the 12 months post-ART initiation being <200 
copies/mL.  
Pre-treatment CD4 Count 
The pre-treatment CD4 count was defined as an individual’s first CD4 count within 6 months of 
diagnosis, when the first CD4 count was reported prior to the estimated date of ART initiation.  
Date of seroconversion  
 To estimate the date of seroconversion in newly diagnosed people, we applied an estimated rate of 
CD4 decline, which was based on previously published estimates from the CASCADE seroconverter 
cohort, to the NYC population, PLWH diagnosed from 2006 to 2015.17 An underlying assumption of the 
CD4 decline model is that among ART-naïve people, the square root of the CD4 cell count decreases 
linearly over time19, and the time since seroconversion can be estimated by applying an estimated rate 
of CD4 decline (from CASCADE cohort) to a population with at least one pre-treatment CD4 count (NYC 
newly diagnosed PLWH).17,20-22  
 The CD4 depletion model relates the square root of the first pre-treatment CD4 count (CD4t) to time 




Where t is the time from HIV seroconversion to the date of the first pre-treatment CD4 count, CD4t is 
the first pre-treatment CD4 count, and the intercept (a0) and the slope (b1) are random variables 
following a normal distribution.  
 The duration of infection (t) is then estimated for an individual by Formula 2, using the previously 
published model parameters.  
 
For Formula 2, to incorporate the error term, the intercept a and slope b, for each person, were 
assumed to follow a bivariate normal distribution N [(a,b), (standard errora, standard errorb), correlation 
coefficient(p)]. The mean intercept and slope, standard errors and correlation coefficient were based on 
published estimates for combinations of sex, age group at seroconversion and risk group from the 
CASCADE cohort (see Song, et al 201617). 
 Since the age group at seroconversion is a necessary parameter, but unknown in our population, we 
used the age at diagnosis as an initial approximation of the age at seroconversion and estimated T using 
age at diagnosis (Formula 2). We then used T to estimate age at seroconversion (Formula 3, below). 44% 
of the cohort was assigned an age group at seroconversion that was earlier than the age group at 
diagnosis, and the remaining 56% stayed in the same age group. Lastly, we re-estimated T using the new 
age at seroconversion (Formula 2).   
 Age at seroconversion was estimated as  
 
 Finally, the date of seroconversion was then estimated by: 
 
 In instances where seroconversion was estimated to occur after diagnosis, the date of 
seroconversion was set to the date of diagnosis. For people diagnosed with acute HIV infection, the date 
of seroconversion was assigned as the date of diagnosis.  
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 Assuming normal distributions and with sex-, age- and risk-specific standard errors described in Song 
et al17 and above in Formulas 1 and 2, we estimated the duration (Ti from seroconversion to first pre-
treatment CD4 count) by sampling for each person 1,000 times and took the average to infer an 
individual’s date of seroconversion and incorporate variance.  
Elapsed time to diagnosis and ART initiation 
 We examined 3 metrics: time from seroconversion to ART initiation, time from seroconversion to 
diagnosis and time from diagnosis to ART initiation. For each metric, we calculated the difference 
between the respective dates and expressed elapsed time as number of years.  
   Statistical analysis 
We generated the mean and median number of years since seroconversion overall and by subgroup 
in 2006 and 2015. We used weighted procedures to handle the sample weights. All analyses were 
conducted in SAS version 9.4 (SAS Institute, Cary, N.C.).  
This study was approved by the institutional review boards at The City University of New York School 
of Public Health and the New York City Department of Health and Mental Hygiene. For these secondary 
analyses, we received a waiver for informed consent under 45 CFR 46.116(d)(2). 
RESULTS  
The analysis included 28,162 NYC residents who were diagnosed with HIV from 2006 to 2015. New 
diagnoses were mostly men (78%), black or Latino/Hispanic (78%), younger (36% aged 13-29, 26% aged 
30-39 years), and men who have sex with men (63%) (Table 1). The median pre-ART CD4 count was 362 
cells/µL (interquartile range, 188-542), with 27% having a pre-ART CD4 count <200 and 30% having a 
pre-ART CD4 count of ≥500. By July 2017, 89% had initiated ART and 69% were virally suppressed one 
year after ART initiation. The annual number of new diagnoses decreased from 2006 (N = 3,227) to 2015 
(N = 2,283). The median pre-ART CD4 count increased from 326 cells/µL (IQR: 132-504) in 2006 to 390 
cells/µL (IQR: 216-571)  in 2015 (Table 2)  
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Estimated time from seroconversion to ART initiation from 2006 to 2015 
 Among people who initiated ART, the mean time from seroconversion to ART initiation decreased 
from 8.0 years (95% CI 7.8-8.2) in 2006 to an average of 5.3 years (5.1-5.6) in 2015, representing a 33% 
decline over a decade (Table 2). The median time from seroconversion to ART initiation was 6.4 years 
and 3.7 years among those diagnosed in 2006 and 2015, respectively. Among people who initiate ART, 
the mean time from seroconversion to diagnosis was reduced by 22%, from 6.5 years (6.3-6.7) in 2006 
to 5.1 years (4.9-5.4) in 2015. Estimates of diagnosis delay (seroconversion to diagnosis) did not vary 
when the denominator was all people diagnosed. The mean time from diagnosis to ART initiation was 
reduced by 87%, from 1.5 years (1.4-1.5) in 2006 to 0.2 years (0.2-0.3) in 2015 (Table 2 and Figure 1).  
Estimated time from seroconversion to ART initiation by Subgroups – 2006 versus 2015 
 Among people who were diagnosed with HIV in 2015 and initiated ART, the estimated time from 
seroconversion to ART initiation was shortest among people who were white (4.3 years, 95% CI:3.7-4.8), 
young (age 13-19 at diagnosis, 4.2 years, 95% CI:3.8-4.5), had both IDU and MSM transmission risk (3.2 
years, 95% CI:2.4-4.1), or were diagnosed at a screening, diagnosis or referral facility (3.3 years, 95% 
CI:2.7-3.8). The estimated time from seroconversion to ART initiation was longest among women (5.9 
years, 95% CI:5.1-6.5), people who were black (6.0 years, 95% CI:5.6-6.4), older (age 50+ at diagnosis, 
6.3 years, 95% CI:5.8-6.9), had heterosexual transmission risk (6.5 years, 95% CI:5.9-7.1), or were 
diagnosed at an inpatient facility (7.0 years, 95% CI:6.6-7.5). From 2006 to 2015 the percentage 
decrease in diagnosis delay (seroconversion to diagnosis) ranged from 38% among MSM and IDU 
(largest decrease) to 11% among people aged 30-39 at diagnosis (smallest decrease). The percentage 
decrease in ART delay (diagnosis to ART initiation) over the period ranged from 94% among white 
people to 77% among both women and people aged 50+ at diagnosis. Estimates of diagnosis delay 
among all people diagnosed were similar to the estimates of diagnosis delay among ART initiators 




 Voluntary HIV testing followed by immediate ART initiation (universal testing and treatment) has 
become an integral part of strategies to eliminate HIV and control the HIV/AIDS epidemic.1,24-30 
Minimizing the time from HIV infection to ART initiation is essential for universal test and treatment to 
be optimally effective. However, neither frontline implementers, nor health agencies or researchers 
have typically focused on quantifying the HIV-infectiousness period, partially due to the absence of 
population-based data on the timing of seroconversion. During 2006-2015, before and after the 2011 
recommendation to ‘treat all’ people with diagnosed HIV regardless of CD4 count, we estimated the 
time from HIV seroconversion to ART initiation in New York City, a major epicenter of the HIV epidemic 
in the US, using population-based surveillance data in which seroconversion events are not observed.17 
Over a period of 10 years, the mean time from seroconversion to ART initiation decreased by one-third 
or 2.7 years, from 8.0 years (7.8-8.2) in 2006 to 5.3 years (5.1-5.6) in 2015.  
 We represented the time from seroconversion to ART initiation as having two phases: 1) from 
seroconversion to diagnosis, and 2) from diagnosis to ART initiation. The time from seroconversion to 
diagnosis declined by 22% or 1.4 years. The time from diagnosis to ART initiation reduced by 87% or 1.3 
years. The time from diagnosis to ART initiation decreased more substantially than the time from 
seroconversion to diagnosis. A little more than half (56% or 1.5/2.7 years) of the overall reduction in the 
time from seroconversion to ART initiation was due to decreases in the time between diagnosis and ART 
initiation, suggesting more emphasis on rapid treatment initiation following diagnosis than on testing for 
earlier identification of people with undiagnosed HIV. While ‘treat all’ policies are increasingly 
implemented, greater efforts and more effective strategies for earlier HIV diagnosis and linkage are 
needed to reduce the much larger time interval between seroconversion and diagnosis, which could 




 In the era of universal test and treat, an estimate of the infectious period from HIV seroconversion 
to ART initiation could become a priority indicator to identify gaps in time and monitor whether HIV 
testing and prevention initiatives are closing such gaps.12,17,20,31 The analytic period (2006 to 2015) 
overlaps with many national and citywide testing and treatment initiatives. These included a) large scale 
testing initiatives (Bronx Knows, Brooklyn Knows and New York Knows) which aimed to make all 
respective residents aware of their HIV status and assist with linkage to HIV care;32,33 b) introduction of a 
new state law which required all health care professionals to offer a voluntary HIV test;33 and c) 
changing state ART guidelines.25,34 New York City’s robust infrastructure to support HIV testing, care and 
treatment likely contributed to reductions in the time from seroconversion to ART initiation.11  
 This study found that people who were born female, were older, black or heterosexual had the 
longest delays in the time from seroconversion to ART initiation in 2015, and the bulk of this delay was 
in the time from seroconversion to diagnosis. Despite long-term and largely successful efforts to 
improve HIV testing in NYC, some individuals and groups are still not being reached. Our findings could 
be used to inform the development of HIV testing initiatives for groups with the longest diagnosis 
delay.11 To achieve the goal of ‘ending the epidemic’ in New York, earlier identification of people with 
undiagnosed HIV infection is necessary so they can be engaged in care and treatment sooner.   
 The following limitations apply. First, the seroconversion estimate is based on previously published 
model parameters, which depend on initial model assumptions (e.g., linearity) and generalizing CD4 
decline from a European seroconverter cohort to NYC residents.17,19,35 The estimates we used from the 
CASCADE cohort were restricted to the HIV subtypes most common in the US (predominately subtype B) 
and should be applicable from that perspective.17 Further, the CD4 decline parameters assume no 
changes in virulence of HIV strains over time, which, if present in NYC, could alter the average rates of 
CD4 decline in the population. If the predominant HIV strains became more or less virulent in NYC, our 
analysis would over or underestimate the time, respectively. Second, we used age at diagnosis to 
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approximate age at infection. Given age at infection should be the same or less than age at diagnosis, 
people may incorrectly remain in an older age group, which may underestimate elapsed time, as rates of 
decline are faster for older groups.      
 Third, people who migrate out of NYC after diagnosis will not have longitudinal laboratory 
information reported to the NYC surveillance system. Therefore, missing pre-treatment data can be 
caused by a lack of engagement in care or migration out of the jurisdiction. The analysis was weighted 
for people missing a CD4 count at diagnosis; however, we would be unable to observe ART initiation 
among people who migrate from NYC prior to initiating ART. To minimize the issue of outmigration, we 
excluded people considered to have left the city because they did not have any HIV-related laboratory 
test information reported the registry within 18 months of diagnosis. Our estimates of time from 
diagnosis to ART should therefore generalize to the population that is diagnosed and initiates ART in the 
city following their HIV diagnosis.  
 Our analysis shows considerable progress in rapid ART initiation following an HIV diagnosis in the era 
of ‘treat all’ recommendations in New York City. This has contributed substantially to declines in the 
infectious period for HIV at the population level over a 10-year period of about 33% overall. Specifically, 
the time from diagnosis to ART initiation decreased by 87%, and is now on average very short. Despite 
these improvements, disparities persist in the ART initiation delay so efforts should focus on subgroups 
for whom progress still needs to be made.  Substantive efforts are needed to reduce the time from 
seroconversion to diagnosis. Targeted HIV testing strategies are needed to more rapidly identify people 
with undiagnosed HIV soon after HIV seroconversion in order to achieve further reductions in HIV 
incidence and mortality in key subgroups who continue to be negatively impacted by the HIV epidemic.   
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TABLES AND FIGURES 
 
Figure 1. Trends in mean or median time from seroconversion to ART initiation (S:A), seroconversion 




2006 2007 2008 2009 2010 2011 2012 2013 2014 2015
Median S:A 6.4 6.2 5.7 5.1 4.8 4.3 4.1 4 3.5 3.7
Mean S:A 8 7.6 7.2 6.7 6.3 5.9 5.6 5.6 5.4 5.3
Median S:D 4.7 4.6 4.3 3.8 3.9 3.5 3.3 3.6 3.3 3.4
Mean S:D 6.5 6.3 5.99 5.61 5.49 5.2 5.09 5.22 5.13 5.14
Median D:A 0.5 0.5 0.4 0.4 0.3 0.3 0.2 0.2 0.2 0.2













Table 1. Demographic Characteristics and Median Pre-treatment CD4 Values of People Diagnosed with 
HIV – New York City, 2006 to 2015 
  
 All Diagnoses 2006-20151 2006 Diagnoses1 2015 Diagnoses1 












Total 28,162 (100.0) 362 (188, 542) 3,227 (100.0) 326 (132, 504) 2,283 (100.0) 390 (216, 571) 
Sex       
Male 21,918 (77.8) 367 (195, 541) 2,360 (73.1) 328 (130, 502) 1,893 (82.9) 394 (225, 576) 
Female 6,244 (22.2) 344 (164, 547) 867 (26.9) 317 (144, 512) 390 (17.1) 349 (182, 545) 
Race/Ethnicity       
Black 12,550 (44.6) 363 (193, 538) 1,535 (47.6) 323 (124, 484) 913 (40.0) 396 (235, 580) 
Latino/Hispanic 9,312 (33.1) 381 (190, 564) 1,063 (32.9) 151 (53, 435) 854 (37.4) 429 (206, 504) 
White 5,110 (18.1) 328 (185, 499) 540 (16.7) 275 (186, 427) 379 (16.6) 365 (171, 531) 
Asian/Pacific Islander 987 (3.5) 342 (164, 522) 70 (2.2) 311 (122, 492) 109 (4.8) 358 (190, 546) 
Other/Unknown 203 (0.7) 417 (240, 594) 19 (0.6) 386 (185, 586) 28 (1.2) 447 (256, 623) 
Age at Diagnosis       
13 - 29 10,023 (35.6) 422 (285, 581) 919 (28.5) 409 (262, 563) 941 (41.2) 435 (315, 603) 
30 - 39 7,224 (25.7) 368 (190, 542) 937 (29.0) 345 (145, 505) 569 (24.9) 375 (185, 554) 
40 - 49 6,318 (22.4) 312 (113, 517) 827 (25.6) 271 (73, 475) 367 (16.1) 325 (118, 552) 
50+ 4,597 (16.3) 240 (78, 440) 544 (16.9) 193 (62, 383) 406 (17.8) 289 (93, 504) 
Transmission Risk       
Men who have sex 
with men (MSM)  17,779 (63.1) 387 (227, 555) 1,698 (52.6) 358 (176, 532) 1,650 (72.3) 404 (240, 582) 
Injection drug use 
(IDU) 1,450 (5.1) 281 (94, 502) 279 (8.6) 218 (60, 433) 55 (2.4) 394 (161, 661) 
MSM & IDU 623 (2.2) 398 (222, 594) 77 (2.4) 377 (179, 576) 44 (1.9) 428 (310, 580) 
Heterosexual contact 8,310 (29.5) 308 (125, 508) 1,173 (36.3) 297 (108, 480) 534 (23.4) 317 (141, 517) 
Facility of Diagnosis       
Outpatient 11,230 (39.9) 399 (244, 573) 1,247 (38.6) 377 (221, 561) 1,067 (46.7) 415 (263, 580) 
Inpatient 11,132 (39.5) 283 (89, 475) 1,359 (42.1) 244 (58, 430) 799 (35.0) 305 (123, 504) 
Screening, Diagnosis or 
Referral 3,388 (12.0) 432 (296, 592) 243 (7.5) 409 (260, 579) 252 (11.0) 473 (328, 659) 
Other 2,412 (8.6) 380 (198, 568) 378 (11.7) 312 (142, 520) 165 (7.2) 371 (196, 567) 
Pre-treatment CD4 
Count       
<200 7,442 (26.4) NA 1,058 (32.8) NA 521 (22.8) NA 
200-349 6,073 (21.6) NA 677 (21.0) NA 490 (21.5) NA 
350-499 6,204 (22.0) NA 668 (20.7) NA 513 (22.4) NA 
500+ 8,443 (30.0) NA 824 (25.5) NA 759 (33.2) NA 
Initiated ART by July 
2017       
Yes 25,021 (88.8) 359 (190, 537) 2,841 (88.0) 331 (144, 510) 2,025 (88.7) 386 (214, 567) 
No 3,141 (11.2) 390 (161, 576) 386 (12.0) 341 (116, 533) 258 (11.3) 398 (241, 607) 
Viral Suppression        
    Yes 19,541 (69.4) 351 (190, 524) 1,850 (57.3) 288 (120, 451) 1,857 (81.3) 387 (217, 566) 
    No 8,621 (30.6) 397 (195, 591) 1,377 (42.7) 405 (186, 590) 426 (18.7) 346 (156, 565) 







Table 2. Estimated annual time from Seroconversion to ART Initiation – New York City, 2006-2015 
   Estimated time from 
seroconversion to ART 
initiation, Years1,2- Among 
ART Initiators 
Diagnosis Delay, Years1,3 – 
Among All Diagnosed 
Persons 
Diagnosis Delay, Years1,2 
– Among ART Initiators 
ART Delay, Years1,2- 
Among ART Initiators 
Year  Weighted N 
(%)1 
Median CD4 (IQR) Medi
an 
Mean (95% CI)  Medi
an 
Mean (95% CI)  Medi
an 
Mean (95% CI)  Medi
an 
Mean (95% CI)  
2006 3,227 (11.5) 326 (132, 504) 6.4 8.0 (7.8, 8.2) 4.6 6.5 (6.3, 6.7) 4.6 6.5 (6.3, 6.7) 0.5 1.5 (1.4, 1.5) 
2007 3,225 (11.5) 335 (144, 513) 6.2 7.6 (7.4, 7.8) 4.4 6.3 (6.0, 6.5) 4.5 6.3 (6.1, 6.5) 0.5 1.3 (1.2, 1.4) 
2008 3,186 (11.3) 341 (166, 531) 5.7 7.2 (7.0, 7.4) 4.1 6.0 (5.8, 6.2) 4.3 6.0 (5.8, 6.2) 0.4 1.2 (1.1, 1.3) 
2009 2,995 (10.6) 366 (187, 535) 5.1 6.7 (6.4, 6.9) 3.7 5.6 (5.4, 5.9) 3.7 5.6 (5.4, 5.8) 0.4 1.1 (1.0, 1.1) 
2010 2,787 (9.9) 359 (200, 542) 4.8 6.3 (6.1, 6.6) 3.8 5.5 (5.3, 5.7) 3.9 5.5 (5.3, 5.7) 0.3 0.9 (0.8, 0.9) 
2011 2,755 (9.8) 379 (211, 559) 4.3 5.9 (5.7, 6.1) 3.4 5.2 (5.0, 5.4) 3.5 5.2 (5.0, 5.4) 0.3 0.7 (0.7, 0.8) 
2012 2,616 (9.3) 381 (216, 563) 4.1 5.6 (5.4, 5.9) 3.2 5.1 (4.9, 5.3) 3.2 5.1 (4.9, 5.3) 0.2 0.5 (0.5, 0.6) 
2013 2,577 (9.2) 376 (213, 550) 4.0 5.6 (5.4, 5.8) 3.5 5.2 (5.0, 5.4) 3.5 5.2 (5.0, 5.5) 0.2 0.4 (0.4, 0.4) 
2014 2,511 (8.9) 382 (212, 558) 3.5 5.4 (5.2, 5.7) 3.2 5.2 (4.9, 5.4) 3.2 5.1 (4.9, 5.4) 0.2 0.3 (0.3, 0.3) 
2015 2,283 (8.1) 390 (216, 571) 3.7 5.3 (5.1, 5.6) 3.3 5.1 (4.9, 5.4) 3.3 5.1 (4.9, 5.4) 0.2 0.2 (0.2, 0.3) 
1. Dataset weighted for imputed transmission risk and persons missing a CD4 at diagnosis 
2. Estimated among all persons who started ART 





Table 3. Estimated time from Seroconversion to ART Initiation by Subgroups – Among Persons who Initiate ART in New York City, 2006 and 
2015  
 2006 Diagnoses 2015 Diagnoses  % change from 2006 to 
2015 
 Estimated time from 
seroconversion to ART 
initiation1 – Among ART 
initiators 
Diagnosis delay2 – 
Among ART initiators 
ART delay3 – Among ART 
initiators 
Estimated time from 
seroconversion to ART 
initiation1 – Among ART 
initiators 
Diagnosis delay2 – 
Among ART initiators 










an Mean (95% CI) 
Medi
an Mean (95% CI) 
Medi
an Mean (95% CI) 
Medi
an Mean (95% CI) 
Medi
an Mean (95% CI) 
Medi
an Mean (95% CI)   
Total 6.4 8.0 (7.8, 8.2) 4.7 6.5 (6.3, 6.7) 0.5 1.5 (1.4, 1.5) 3.7 5.4 (5.1, 5.6) 3.4 5.1 (4.9, 5.4) 0.2 0.2 (0.2, 0.3) 21.5 86.7 
Sex               
Male 6.5 8.0 (7.7, 8.2) 4.6 6.5 (6.2, 6.7) 0.6 1.5 (1.5, 1.6) 3.6 5.3 (5.0, 5.5) 3.3 5.0 (4.8, 5.3) 0.2 0.2 (0.2, 0.3) 23.1 86.7 
Female 6.2 7.9 (7.4, 8.4) 4.8 6.6 (6.1, 7.1) 0.4 1.3 (1.2, 1.4) 4.2 5.9 (5.3, 6.6) 3.9 5.7 (5.0, 6.4) 0.2 0.3 (0.2, 0.3) 13.6 76.9 
Race/Ethnicity               
Black  6.9 8.4 (8.1, 8.7) 5.0 6.9 (6.5, 7.2) 0.5 1.5 (1.4, 1.6) 4.2 6.0 (5.6, 6.4) 3.9 5.7 (5.3, 6.1) 0.2 0.3 (0.2, 0.3) 17.4 86.7 
Latino/Hispanic 6.4 8.0 (7.6, 8.4) 4.7 6.6 (6.2, 7.0) 0.5 1.4 (1.3, 1.5) 3.5 5.2 (4.8, 5.6) 3.3 5.0 (4.6, 5.4) 0.2 0.3 (0.2, 0.3) 24.2 85.7 
White 5.5 6.7 (6.2, 7.1) 3.2 5.1 (4.6, 5.6) 0.7 1.6 (1.4, 1.7) 2.2 4.3 (3.7, 4.8) 1.9 4.1 (3.5, 4.6) 0.1 0.2 (0.2, 0.2) 19.6 93.8 
API 6.8 8.5 (7.0, 10.0) 6.0 7.1 (5.5, 8.7) 0.7 1.4 (1.0, 1.9) 4.6 5.7 (4.6, 6.8) 4.5 5.4 (4.3, 6.5) 0.1 0.2 (0.2, 0.3) 23.9 92.9 
Other/Unknown 7.1 9.5 (5.9, 13.0) 6.7 8.5 (4.7, 12.3) 0.6 1.0 (0.3, 1.6) 3.1 6.3 (2.8, 9.7) 2.9 6.1 (2.6, 9.6) 0.1 0.2 (0.1, 0.3) 28.2 90.0 
Age at Diagnosis               
13 – 29 5.9 6.9 (6.5, 7.3) 3.5 5.0 (4.6, 5.4) 1.0 1.9 (1.7, 2.1) 2.8 4.2 (3.8, 4.5) 2.4 3.9 (3.6, 4.2) 0.2 0.3 (0.2, 0.3) 22.0 84.2 
30 – 39 6.1 8.1 (7.6, 8.5) 4.0 6.6 (6.2, 7.1) 0.5 1.5 (1.3, 1.6) 3.8 6.2 (5.6, 6.8) 3.5 5.9 (5.3, 6.5) 0.1 0.2 (0.2, 0.3) 10.6 86.7 
40 – 49 7.0 8.8 (8.3, 9.2) 5.5 7.4 (7.0, 7.9) 0.4 1.3 (1.2, 1.5) 4.4 6.3 (5.6, 7.0) 4.0 6.1 (5.4, 6.8) 0.1 0.2 (0.2, 0.3) 17.6 84.6 
50+ 7.5 8.4 (7.9, 8.8) 6.9 7.4 (7.0, 7.9) 0.3 0.9 (0.8, 1.1) 4.9 6.3 (5.8, 6.9) 4.8 6.1 (5.5, 6.6) 0.1 0.2 (0.2, 0.3) 17.6 77.8 
Transmission Risk               
MSM 6.1 7.7 (7.3, 8.0) 4.2 6.0 (5.7, 6.3) 0.7 1.6 (1.5, 1.8) 3.4 5.1 (4.8, 5.4) 3.1 4.9 (4.6, 5.2) 0.2 0.2 (0.2, 0.3) 18.3 87.5 
IDU 6.8 7.3 (6.9, 7.8) 5.2 6.1 (5.6, 6.6) 0.5 1.2 (1.1, 1.4) 3.5 4.5 (3.6, 5.4) 2.9 4.1 (3.2, 5.0) 0.2 0.4 (0.3, 0.5) 32.7 66.7 
MSM & IDU 6.4 6.8 (6.1, 7.5) 2.7 4.7 (3.8, 5.5) 0.9 2.1 (1.7, 2.5) 2.1 3.2 (2.4, 4.0) 1.5 2.9 (2.0, 3.7) 0.2 0.3 (0.2, 0.5) 38.3 85.7 
Heterosexual 6.8 8.6 (8.2, 9.0) 5.5 7.4 (6.9, 7.8) 0.4 1.2 (1.1, 1.3) 4.9 6.5 (5.9, 7.1) 4.7 6.3 (5.7, 6.8) 0.1 0.2 (0.2, 0.3) 14.9 83.3 
Facility of 
Diagnosis               
Outpatient 5.6 6.7 (6.4, 7.0) 3.3 5.1 (4.8, 5.4) 0.6 1.6 (1.5, 1.7) 3.0 4.6 (4.3, 5.0) 2.7 4.4 (4.1, 4.7) 0.2 0.2 (0.2, 0.3) 13.7 87.5 
Inpatient 8.1 9.4 (9.0, 9.7) 6.7 8.2 (7.8, 8.6) 0.3 1.2 (1.1, 1.3) 5.5 7.0 (6.6, 7.5) 5.2 6.8 (6.3, 7.3) 0.1 0.2 (0.2, 0.3) 17.1 83.3 
SDR 5.4 6.3 (5.7, 7.0) 2.9 4.4 (3.7, 5.2) 0.9 1.9 (1.6, 2.2) 1.7 3.3 (2.7, 3.8) 1.3 3.0 (2.5, 3.5) 0.2 0.3 (0.2, 0.3) 31.8 84.2 
Other 7.0 8.3 (7.6, 9.0) 5.2 6.6 (6.0, 7.3) 0.7 1.7 (1.5, 1.9) 4.1 6.0 (4.9, 7.1) 4.0 5.7 (4.6, 6.8) 0.2 0.3 (0.3, 0.4) 13.6 82.4 
API: Asian/Pacific Islander, ART: Antiretroviral treatment, IDU: Injection drug use history, MSM: men who have sex with men, SDR: screening, diagnosis or referral agency 
1 Estimated time from seroconversion to ART is estimated among all persons who initiated ART and may not be the sum of the diagnosis and ART delay as not all diagnosed persons initiated ART 
2 Diagnosis delay refers to the time (years) from the estimated date of seroconversion to diagnosis and is estimated among all persons diagnosed 
3 ART delay refers to the time (years) from diagnosis to ART initiation and is estimated among all persons who initiate ART 
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Supplemental Table 1. Estimated time from Seroconversion to Diagnosis by Subgroups – Among 2006 
and 2015 diagnoses, New York City 
  2006 Diagnosis delay2 – 
Among all diagnosed 
persons  
2015 Diagnosis delay2 – 
Among all diagnosed 
persons 
% Decrease in 
Diagnosis 
Delay from 
2006 to 2015  
  Median Mean Median Mean   
Total 4.6 6.5 (6.3, 6.7) 3.3 5.1 (4.9, 5.4) 21.5 
Sex           
Male 4.5 6.5 (6.2, 6.7) 3.3 5.0 (4.7, 5.3) 23.1 
Female 4.7 6.5 (6.0, 6.9) 3.9 5.8 (5.1, 6.5) 10.8 
Race/Ethnicity           
Black 4.8 6.8 (6.5, 7.1) 3.9 5.8 (5.4, 6.1) 14.7 
Latino/Hispanic 4.7 6.7 (6.3, 7.1) 3.1 4.9 (4.5, 5.3) 26.9 
White 3.2 5.1 (4.6, 5.6) 1.8 4.0 (3.5, 4.5) 21.6 
API 5.8 6.9 (5.4, 8.4) 4.6 5.8 (4.6, 6.9) 15.9 
Other/Unknown 8.0 9.1 (6.0, 12.2) 2.9 5.7 (3.0, 8.3) 37.4 
Age at Diagnosis         
13 – 29 3.2 4.9 (4.6, 5.3) 2.4 3.8 (3.5, 4.2) 22.4 
30 – 39 4.0 6.7 (6.2, 7.1) 3.4 6.0 (5.4, 6.6) 10.4 
40 – 49 5.5 7.4 (6.9, 7.8) 4.1 6.2 (5.6, 6.9) 16.2 
50+ 6.8 7.4 (7.0, 7.8) 4.4 5.9 (5.4, 6.4) 20.3 
Transmission Risk         
MSM 4.1 6.0 (5.7, 6.3) 3.1 4.9 (4.6, 5.1) 18.3 
IDU 5.5 6.3 (5.9, 6.8) 2.3 3.9 (3.1, 4.8) 38.0 
MSM & IDU 2.7 4.5 (3.8, 5.3) 1.7 2.7 (2.0, 3.4) 40.0 
Heterosexual 5.2 7.2 (6.8, 7.6) 4.7 6.3 (5.8, 6.9) 12.5 
Facility of Diagnosis           
Outpatient 3.1 5.0 (4.7, 5.3) 2.6 4.3 (4.0, 4.6) 14.0 
Inpatient 6.9 8.2 (7.9, 8.6) 5.2 6.9 (6.4, 7.3) 15.9 
SDR 2.8 4.3 (3.7, 5.0) 1.3 3.0 (2.5, 3.5) 30.2 
Other 4.8 6.4 (5.8, 7.0) 3.8 5.6 (4.7, 6.6) 12.5 
API: Asian/Pacific Islander, ART: Antiretroviral treatment, IDU: Injection drug use history, MSM: men who have sex 
with men, SDR: screening, diagnosis or referral agency 
1 Estimated time from seroconversion to ART is estimated among all persons who initiated ART and may not be 
the sum of the diagnosis and ART delay as not all diagnosed persons initiated ART 
2 Diagnosis delay refers to the time (years) from the estimated date of seroconversion to diagnosis and is 
estimated among all persons diagnosed 





CHAPTER 5. DISCUSSION 
INTRODUCTION 
Voluntary HIV testing followed by immediate ART initiation (universal testing and treatment) has 
become an integral part of strategies to control the HIV/AIDS epidemic.1-8 Minimizing the time from HIV 
infection to ART initiation is essential for universal test and treatment to be optimally effective. In New 
York City, the ‘treat all’ recommendation, immediate treatment for all people diagnosed with HIV, was 
made in late 2011, and efforts to ‘treat all’ were contemporaneous with roll out of large-scale HIV 
testing initiatives in NYC.9-11 The overarching goal of this dissertation was to examine trends in the 
timeliness of HIV diagnosis and ART initiation using data from the population-based New York City HIV 
surveillance registry before, during and after the “treat all” recommendation, including methodologic 
work related to metrics for timeliness.  
SUMMARY OF RESULTS 
In the first aim, I examined the timeliness of diagnosis and treatment initiation in the universal test 
and treatment era. Among 9987 NYC residents with HIV diagnosed from 2012 to 2015, diagnosis was 
early (i.e., with CD4>500 cells/uL or with AHI) in 35%, and 87% started ART by June 2017. The annual 
proportion of persons with early diagnosis did not increase appreciably (35% in 2012 vs 37% in 2015; P = 
.08, Cochran-Armitage test for trend). Overall, 69% of persons had started ART at 6 months after 
diagnosis. The time from diagnosis to ART initiation decreased from year to year. Within 6 months of 
diagnosis, 62%, 67%, 72% and 77% of persons with HIV diagnosed in 2012, 2013, 2014, or 2015, 
respectively, had started ART, with median (interquartile range) times to ART initiation of 3.34 (1.34–
12.75), 2.62 (1.28–10.13), 2.16 (1.15–7.11), and 2.03 (1.11–5.61) months, respectively. 
In the second and third aims, I adapted a CD4 decline model to estimate the timing of 
seroconversion in a large cohort of newly diagnosed people and estimated the timeliness of diagnosis 
and treatment initiation overall and among sex, age and HIV transmission risk sub-groups. Among 
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28,162 people diagnosed with HIV during 2006-2015, 89% initiated ART by June 2017. The median CD4 
count at diagnosis increased modestly over a 10-year period from 326 (Interquartile range (IQR):132-
504) to 390 (IQR:216-571) cells/µL from 2006-2015. The estimated average time from seroconversion to 
ART initiation decreased by 33% from 8.0 years (95% confidence interval [CI]:7.8-8.2) in 2006 to 5.4 
years (95%CI: 5.1-5.6) in 2015. Contributing to the reduction in time to ART initiation, the estimated 
average time from seroconversion to diagnosis decreased by 22%, from 6.5 years (95% CI:6.3-6.7) to 5.1 
years (95% CI:4.9-5.4) from 2006-2015, and the average time from diagnosis to ART initiation decreased 
by 87%, from 1.5 years (95% CI:1.4-1.5) to 0.2 years (95% CI:0.2-0.3) from 2006-2015. People who were 
born female, were older, black or had heterosexual transmission risk had the longest delays in the time 
from seroconversion to ART initiation in 2015, and the bulk of these delays was in the time from 
seroconversion to diagnosis.  
IMPLICATIONS FOR POLICY  
We represented the time from seroconversion to ART initiation as having two phases: 1) from 
seroconversion to diagnosis, and 2) from diagnosis to ART initiation. The time from seroconversion to 
diagnosis declined by 22% or 1.4 years during the 10-year period from 2006-15. The time from diagnosis 
to ART initiation reduced by 87% or 1.3 years. Relative to the time from seroconversion to diagnosis, the 
time from diagnosis to ART initiation decreased more substantially. A little more than half (56% or 
1.5/2.7 years) of the overall reduction in the time from seroconversion to ART initiation was due to 
decreases in the time between diagnosis and ART initiation, suggesting more emphasis on or 
effectiveness of rapid treatment initiation following diagnosis than on testing for earlier identification of 
people with undiagnosed HIV. While ‘treat all’ policies are increasingly implemented, greater efforts and 
more effective strategies for earlier HIV diagnosis and linkage are needed to reduce the much larger 
time interval between seroconversion and diagnosis, which could result in the substantial declines in 
incidence and mortality needed to ‘end the HIV epidemic’ as a public health threat. 
66 
 
In the era of universal test and treat, an estimate of the infectious period from HIV seroconversion 
to ART initiation should become a priority indicator to identify gaps in time and monitor whether HIV 
testing and prevention initiatives are closing such gaps.12-15 The aim 3 analytic period (2006 to 2015) 
overlaps with many national and citywide testing and treatment initiatives. These included a) large scale 
testing initiatives (Bronx Knows, Brooklyn Knows and New York Knows) which aimed to make all 
respective residents aware of their HIV status and assist with linkage to HIV care;16,17 b) introduction of a 
new New York state law which required all health care professionals to offer a voluntary HIV test;17 and 
c) expanding local ART guidelines.3,18 New York City’s robust infrastructure to support HIV testing, care 
and treatment likely contributed to reductions in the time from seroconversion to ART initiation.11  
Despite long-term and largely successful efforts to improve HIV testing in NYC, some individuals and 
groups are still not being reached (e.g., female, older, black or heterosexual people). This points to the 
importance of targeted versus universal approaches of testing to reach undiagnosed persons. Our 
findings could be used to inform the development of HIV testing initiatives targeting groups with the 
longest diagnosis delay.11 To achieve the goal of ‘ending the epidemic’ in New York, earlier identification 
of individuals with undiagnosed HIV infection is necessary so they can be engaged in care and treatment 
sooner.  
FURTHER RESEARCH 
Validate ART proxy. We used a laboratory-based proxy to estimate the date of ART initiation based 
on the earlier of 1) a 1-log decline in viral load within 2 months or 2) a switch from undetectable to 
detectable viral load. Our proxy metric of ART initiation may have incorrectly attributed some post-
treatment CD4 measures to the pre-treatment period. In our (Braunstein, Nash and Robertson) previous 
validation study, the nadir of the CD4 trajectory, with CD4 falling until ART initiation and rebounding 
after ART initiation, corresponded with the estimated date of ART initiation for 67% of the population. 
Future work should validate the ART proxy with gold standard clinical data on ART initiation.   
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Validate estimates of the timing of seroconversion. We estimated seroconversion based on 
previously published model parameters, which depend on initial model assumptions (e.g., linearity) and 
generalizing CD4 decline from a European seroconverter cohort to NYC residents.12,19,20  Further, the CD4 
decline parameters assume no changes in virulence of HIV strains over time, which, if present in NYC, 
could alter the average rates of CD4 decline in the population. Future research should attempt to 
validate the estimates of time from seroconversion to diagnosis, perhaps among people with HIV 
intertest intervals documented in medical records or in more recent seroconverter cohorts. In our 
validation (aim 2b), we were limited by inaccuracies in self-reported interest intervals and small sample 
sizes.  
Explore additional methods for incorporating variance around estimates of timing of 
seroconversion. We estimated the duration (Ti from seroconversion to first pre-treatment CD4 count) by 
sampling for each person 1,000 times and took the average to infer an individual’s date of 
seroconversion and incorporate variance. However, other methods should be explored for incorporating 
variance, including re-weighting the data to incorporate all 1,000 samples per individual or developing 
prediction intervals.21,22 
Evaluate the impact of universal test and treatment efforts on population incidence. Four large-
scale, community-based randomized controlled intervention trials (ANRS, Ya Tse, SEARCH and PopART) 
aimed to assess the impact of universal test and treat strategies with community HIV incidence as a 
primary outcome. All four trials were set in sub-Saharan Africa. Preliminary evidence from these trials 
relating to the impact of universal test and treat on population HIV incidence is mixed, with two of the 
four showing universal test and treat reduces population incidence.23-26  
The CD4 decline approach allowed us to estimate when people seroconverted and is being used to 
estimate incidence. Given the inconsistent results from trials, more studies on the impact of UTT are 
needed. Potentially, we could design an ecologic study using incidence estimates from the CD4 decline 
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model as the outcome and, for example, population-based viral load suppression from HIV surveillance 
and population-based HIV testing from the Community Health Survey could serve as model inputs.  
Understand HIV testing coverage. To achieve the goal of ‘ending the epidemic’ in New York, earlier 
identification of individuals with undiagnosed HIV infection is necessary so they can be engaged in care 
and treatment sooner. This requires understanding coverage of HIV Testing in New York City and if 
testing efforts are reaching the right people and at the right frequency. Such information could be used 
in triangulation with data on delays in seroconversion to further inform targeted testing approaches.  
LIMITATIONS  
The dissertation has the following limitations, which have also been outlined in individual chapters. 
First, the seroconversion estimate is based on previously published model parameters, which depend on 
initial model assumptions (e.g., linearity) and generalizing CD4 decline from a European seroconverter 
cohort to NYC residents (Aims 2-3).12,19,20 The estimates we used from the CASCADE cohort were 
restricted to the HIV subtypes most common in the US (predominately subtype B) and should be 
applicable from that perspective.12 Further, the CD4 decline parameters assume no changes in virulence 
of HIV strains over time, which, if present in NYC, could alter the average rates of CD4 decline in the 
population. If the predominant HIV strains became more or less virulent in NYC, our analysis would over 
or underestimate the time, respectively. When seroconversion was estimated to occur after diagnosis, 
the date of seroconversion was set to the date of diagnosis. The model and estimation may not perform 
as well for persons with high diagnostic CD4 counts (>500 cells).  
Second, we used age at diagnosis to approximate age at seroconversion (Aims 2-3). Older age 
groups have faster rates of CD4 decline than younger age groups. A CD4 decline of 200 cells (from 500 to 
300) in a person age 65 versus 35 at infection may translate to a 2 versus 5 year delay in diagnosis, 
respectively. The age at seroconversion is by defintion the same or less than the age at diagnosis, and 
people may have been incorrectly classified as being in the wrong (older) age group at seroconversion 
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based on their age at diagnosis. Consequently, diagnosis delay may be underestimated elapsed time (as 
2 years and not 5 years in prior example) for persons incorrectly assigned to an older age group. Third, 
our proxy metric of ART initiation may have incorrectly attributed some post-treatment CD4 measures 
to the pre-treatment period (Aims 1-3). Fourth, CD4 measurements have been shown to be highly 
variable due to factors such as smoking, menstruation, physical exercise, comorbidities, and laboratory 
measurement error (Aims 1-3).27,28 The CD4 decline approach should be used at the population-level and 
should not be used to present estimates of the timing of seroconversion for individuals.  
Finally, missing data in the NYC surveillance system is caused by migration out of the jurisdiction or 
people not receiving medical care in NYC (Aims 1-3). We do not have information on migration, and 
substantial evidence from New York City and other jurisdictions suggests that not accounting for out-
migration results in surveillance-based care measures that are lower than the truth.29-35 For example, 
accounting for outmigration in NYC, increased retention estimates from 63% to 91% in 2012.29 To 
minimize the potential biasing effect of out-migration or loss to the surveillance system, we restricted 
the analysis to individuals who had at least one laboratory event reported to the NYC surveillance 
registry within 18 months of diagnosis, as these individuals were likely to be receiving medical care  in 
NYC. Thus, this restriction would exclude persons who remain in the city and do not link to care within 
18 months. Our estimates of time from diagnosis to ART should therefore generalize to the population 
that is linked to NYC HIV medical care within 18 months following their HIV diagnosis. Estimates of 
median time should not be biased, as >50% of people initiated ART by 18 months. 
STRENGTHS AND PUBLIC HEALTH RELEVANCE  
Characterizing the timeliness with which HIV diagnosis and ART initiation occur by geographic, 
demographic and other subgroups can be used to inform universal testing and treatment 
implementation and policy. To realize the full individual and population benefits from expanded 
treatment guidelines, HIV-infected persons need to be diagnosed earlier in the course of infection, 
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underscoring the need for continued efforts to expand and focus HIV testing efforts to achieve earlier 
diagnosis of HIV in population groups with historically low testing frequency and high rates of late HIV 
diagnosis. 
To the best of my knowledge, this dissertation is the first to present population-based estimates of 
the amount of time between seroconversion and ART initiation in the United States. Arguably, the 
primary reason these data do not exist is because the timing of seroconversion is almost never known 
and because population-based data on the timing of ART initiation are limited to clinical cohorts, which 
are not population-representative, or to small numbers of newly diagnosed persons.36,37 Given that all 
states, the District of Columbia and U.S. territories have mandatory reporting of all diagnosed cases of 
HIV infection12 and most have comprehensive laboratory reporting, the development of this method and 
metric using local data has broad implications and utility in terms of monitoring the epidemic and 
progress toward controlling the epidemic. Local estimates are paramount, given that ending the 
epidemic initiatives emphasize the need to focus the public health response on the cities and 
communities most affected by HIV.38  
CONCLUSIONS 
 In the last decade, the time to ART initiation was reduced in tandem with expanded HIV testing and 
treatment policies in New York City, a major epicenter for HIV in the U.S. We found considerable 
progress in rapid ART initiation: a) the proportion of persons initiating ART within 6 months of diagnosis 
increased from 2012 to 2015, b) the time from seroconversion to ART initiation decreased by 33% over a 
10 year period, and c) the time from diagnosis to ART initiation decreased by 87%. Despite these 
improvements, disparities persist in ART initiation delay so efforts should focus on subgroups for whom 
progress still needs to be made. Finally, substantive efforts are needed to reduce delays in HIV diagnosis 
(i.e., the time from seroconversion to diagnosis). Targeted (versus universal) HIV testing strategies are 
needed to more rapidly identify individuals with undiagnosed HIV soon after HIV seroconversion in 
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order to achieve further reductions in HIV incidence and mortality in key subgroups who continue to be 
negatively impacted by the HIV epidemic.   
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APPENDIX TO CHAPTER 3: VALIDATING ESTIMATES OF DIAGNOSIS 
DELAY (AIM 2B) 
OBJECTIVE  
To validate dates of seroconversion estimated via the CD4 decline approach, we compared the 
mean values of (1) estimated seroconversion dates based on the CD4 decline approach with (2) 
estimated seroconversion dates based on an HIV intertest interval from people who were a) sampled 
and interviewed for the case-surveillance-based sampling (CSBS) project and b) diagnosed with HIV from 
2006 to 2015.  
METHODS  
Population. The analysis required merging two data sources. The first data source was the HIV 
Surveillance Registry. We included people who were diagnosed from 2006 to 2015, aged >13 years at 
HIV diagnosis with their laboratory information reported through June 30, 2017 (N=32,556). We 
excluded people who did not have at least one VL or CD4 test reported to the Registry within 18 months 
of diagnosis (N=4,394 excluded, leaving N=28,162 in analytic cohort), as people without a VL or CD4 for 
18 months either moved out of NYC or were not receiving HIV medical care within NYC.    
The second data source was interview data from the case-surveillance-based sampling (CSBS) 
project. The CSBS project provides information about clinical outcomes and behaviors of people living 
with HIV with respect to care seeking and care utilization. People are randomly sampled from the HIV 
surveillance registry and recruited for a CSBS interview. 1 We included people who were interviewed for 
CSBS from 2012 to 2014 and reported a diagnosis date within the 5 years before the CSBS interview and 
reported a last negative HIV test date (N = 134).  
Metrics. We calculated 3 estimates of diagnosis delay (time in years from seroconversion to HIV 
diagnosis). The first estimate of diagnosis delay relied on CSBS data, and diagnosis delay was calculated 
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as the midpoint between the reported last negative HIV test and the reported date of diagnosis. The 
second estimate of diagnosis delay relied on CSBS and Registry data, and diagnosis delay was calculated 
as the midpoint between the CSBS reported last negative HIV test and the Registry date of diagnosis. 
The third estimate of diagnosis delay was based on the CD4 decline approach (as previously described in 
Chapter 4).  
RESULTS  
134 people reported that they were diagnosed within the 5 years before the CSBS interview and 
reported a last negative HIV test date (Figure 1). We merged the CSBS sample with our analytic cohort 
(N = 23,538 people who were diagnosed from 2006 to 2015 and had at least one laboratory value (CD4 
or viral load) and had a pre-treatment CD4 count). Among the 134 people who reported a last negative 
HIV test date, N = 79 (59%) did not overlap with the analytic cohort and N = 55 (41%) people overlapped 
with the analytic cohort.  
Among the 79 people who were not in the analytic cohort, N = 6 did not match with the HIV 
Surveillance Registry. N = 73 people were in the HIV surveillance registry but not the analytic cohort 
because they were missing the diagnosis date variable used to create the cohort (i.e., HIVDXDTAFTER). 
The 73 people in the Registry but not the analytic cohort reported dates of diagnosis that were much 
later than their registry date of diagnosis (73% (N=53/73) reported a diagnosis date from 2006 to 2012 
versus 18% (N=13/73) with a Registry date of diagnosed from 2006 to 2012) (Table 1).  
Among the 73 people, 59 (81%) had at least 1 laboratory test reported as of June 30, 2017. 
Among the 59 with any laboratory events, 3 people had only 1 event reported, and mean number of 
laboratory events reported per person was N = 44 (median = 41). The length of time from diagnosis to 
first report date was quite long (mean of 47 months), this was due to diagnoses happening prior to 
mandatory laboratory reporting (60/73 or 82%) were diagnosed before 2006.  
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Among the 55 people who were in the CSBS and in the analytic dataset, 17 (30%) were excluded 
due to missing a pre-treatment CD4 count or due to a last negative HIV test date being reported after 
the date of diagnosis (thus, we were unable to calculate a self-reported date of seroconversion). We 
were left with N=38 people in the CSBS and in the analytic cohort (Figure 1).  
Reported dates resulted in shorter estimates of diagnosis delay. The average diagnosis delay 
was a) 1.6 years based on reported date of diagnosis and reported negative HIV test date, b) 4.8 years 
based on Registry date of diagnosis and reported negative HIV test date, and c) 6.3 years based on CD4 
decline approach (Table 2).  
DISCUSSION 
In a small sample of people (N=34) with an estimated diagnosis delay based on self-reported 
intertest intervals and the CD4 decline approach, the CD4 decline approach resulted in longer estimates 
of delay than the self-reported HIV intertest interval. The difference between the two estimates based 
on an HIV intertest interval was changing from self-report to Registry dates of diagnosis. The finding that 
diagnosis delays were shorter when using a reported versus Registry date of diagnosis (mean of 1.6 
versus 4.8 years, respectively) implies that people report a date of diagnosis that is more recent than the 
date documented in the Registry. A similar observation can be drawn from the 73 people who were in 
the Registry but not the analytic cohort; reported dates of diagnosis were more recent than Registry 
dates of diagnosis (73% and 18% diagnosed from 2006 to 2012, respectively), and the group appeared to 
be aware of the HIV diagnosis (81% (59/73) ever received HIV care, as indicated by laboratory 
reporting).   
Thus, self-reported dates of diagnosis are not accurate. This is notable because a diagnosis date 
is arguably a more salient event than a negative test date. If people do not accurately remember 
diagnosis dates, then they are unlikely to remember the last negative test date. Self-reported HIV test 
dates appear to have low validity. Therefore, our measures of diagnosis delay based on reported HIV 
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intertest interval date would be expected to have low validity and reported intertest intervals are not a 
good metric to use for validating the diagnosis delay based on the CD4 decline approach. We suggest 
this analysis be completed among a population with intertest intervals that do not rely on patient recall, 
perhaps from a medical clinic or sexually transmitted disease clinic.  
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TABLES AND FIGURES 




Table 1. Comparison of Self-Report Dates of Diagnosis and Registry Dates of Diagnosis among the 73 
People in the Registry but Not Matching with the Analytic Cohort. 
HIVDXDT 
(Registry) 
N = 73 Self-Report 
Diagnosis Date  
N = 73 
2006-2012 13 2006-2012 53 
Prior to 2006 60 Prior to 2006 20 
 
134 Persons in CSBS 
who Report a Last 
Negative Test Date
3 people in CSBS 
dataset without 
cityno / unable to 
match with Registry
76 people not in my 
analytic dataset (have 
cityno in CSBS)
3 people have a 
cityno in CSBS but do 
not match with the 
OCT 17 frozen
73 people do not 
have hivdxdtafter / 
unable to match with 
cohort
55 people in analytic 




8 report last negative 
HIV test that is after 
Registry DXDT
38 report last 
negative test date 




Table 2. Estimates (Years) of Diagnosis Delay (Seroconversion to Diagnosis) Among the 38 People with 










CD4 decline estimate  38 6.34 4.95 5.42 0.73 9.39 0 18.54 
Using Registry diagnosis 
date and self-report last 
negative test date 
38 4.77 3.7 3.97 0.73 8.55 0 13.77 
Using self-reported 
diagnosis date and self-
reported last negative test 
date  
38 1.61 2.34 0.5 0.25 1.62 0.12 12.07 
 
